// MEDICINE Questions
// Auto-generated from questions.ts
// Total Questions: 51

import { Question } from '../types';

export const questions: Question[] = [
{
    id: "neet-pg-2024-1",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Male not responding to O-2, diagnosis ARDS. What is the role of IL-8 in ARDS?",
    options: [
      "Endothelial cell activation",
      "Requirement of neutrophil",
      "Macrophage activation",
      "Promote surfactant production"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Requirement of neutrophil (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Acute Respiratory Distress Syndrome (ARDS)** is characterized by acute onset of **bilateral pulmonary infiltrates** with severe **hypoxemia** that is **refractory to oxygen therapy**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå ROLE OF IL-8 IN ARDS:\n\n**Interleukin-8 (IL-8)**, also known as **CXCL8**, is a potent **neutrophil chemoattractant** and one of the most important cytokines in ARDS pathogenesis.\n\n**PRIMARY FUNCTION OF IL-8:**\n\n‚Ä¢ IL-8 is a **chemokine** specifically responsible for **neutrophil recruitment and chemotaxis** ‚≠ê\n\n‚Ä¢ It binds to **CXCR1 and CXCR2 receptors** on neutrophils\n\n‚Ä¢ This binding triggers **neutrophil migration** from the bloodstream into the **alveolar space**\n\n‚Ä¢ **Neutrophil accumulation** in the lungs is a **HALLMARK of ARDS** üéØ\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö° PATHOPHYSIOLOGY CASCADE:\n\n**1.** Initial insult (**sepsis, trauma, pneumonia, aspiration**) triggers inflammatory response\n\n**2.** Alveolar macrophages and epithelial cells **release IL-8**\n\n**3.** IL-8 acts as a **potent chemoattractant** for neutrophils ‚≠ê\n\n**4.** **Massive neutrophil infiltration** occurs in lung tissue\n\n**5.** Activated neutrophils release:\n   ‚Üí **Proteases** (elastase, collagenase)\n   ‚Üí **Reactive oxygen species (ROS)**\n   ‚Üí **Inflammatory mediators**\n\n**6.** These substances cause:\n   ‚Üí **Endothelial injury**\n   ‚Üí **Increased capillary permeability** ‚≠ê\n   ‚Üí **Alveolar damage**\n   ‚Üí **Protein-rich edema** fluid accumulation\n\n**7.** Result: **Impaired gas exchange** and **respiratory failure**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n‚Ä¢ **Endothelial cell activation**: This is done by **TNF-Œ± and IL-1**, NOT primarily IL-8\n\n‚Ä¢ **Macrophage activation**: This is mediated by **IFN-Œ≥ and GM-CSF**\n\n‚Ä¢ **Promote surfactant production**: IL-8 does **NOT** promote surfactant; ARDS actually has **surfactant dysfunction**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ KEY CONCEPT FOR EXAM:\n\n**IL-8 = THE MAJOR NEUTROPHIL CHEMOATTRACTANT IN ARDS** ‚≠ê‚≠ê‚≠ê\n\nElevated **IL-8 levels in bronchoalveolar lavage (BAL) fluid** correlate with:\n‚Ä¢ Disease severity\n‚Ä¢ Poor prognosis\n‚Ä¢ Mortality\n\nStudies show that **blocking IL-8** or neutrophil migration can reduce ARDS severity in experimental models.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° CLINICAL CORRELATION:\n\nPatients with ARDS have **markedly elevated IL-8 levels** in their:\n‚Ä¢ Bronchoalveolar lavage (BAL) fluid\n‚Ä¢ Serum\n\nThe degree of **neutrophil infiltration** (and thus IL-8 activity) directly correlates with:\n‚Ä¢ Severity of **hypoxemia** (P/F ratio)\n‚Ä¢ **Mortality** rate",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-2",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient presents with the finding as shown, What is the best investigation for\nWilson‚Äôs disease?",
    options: [
      "Urine Copper",
      "Hepatic copper",
      "S. Ceruloplasmin",
      "MRI Brain"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Hepatic copper (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Wilson's disease** (hepatolenticular degeneration) is an **autosomal recessive disorder** of copper metabolism caused by mutations in the **ATP7B gene** on **chromosome 13**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå PATHOPHYSIOLOGY:\n\n**NORMAL COPPER METABOLISM:**\n\n‚Ä¢ Dietary copper absorbed in **duodenum and jejunum**\n\n‚Ä¢ Transported to **liver** bound to albumin\n\n‚Ä¢ In hepatocytes, copper is incorporated into **ceruloplasmin** by **ATP7B protein**\n\n‚Ä¢ Excess copper **excreted in bile** (main excretory pathway)\n\n‚Ä¢ Ceruloplasmin-bound copper circulates in blood\n\n**WILSON'S DISEASE (ATP7B defect):**\n\n‚Ä¢ **Defective ATP7B** ‚Üí Cannot incorporate copper into ceruloplasmin\n\n‚Ä¢ **Defective biliary copper excretion** ‚≠ê\n\n‚Ä¢ Copper accumulates in **LIVER FIRST** (primary site) üéØ\n\n‚Ä¢ Eventually overflows to other organs:\n  ‚Üí **Brain** (basal ganglia, putamen)\n  ‚Üí **Cornea** (Kayser-Fleischer rings)\n  ‚Üí **Kidneys** (Fanconi syndrome)\n  ‚Üí **Heart** (cardiomyopathy)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ DIAGNOSTIC INVESTIGATIONS:\n\n‚òÖ **HEPATIC COPPER CONTENT (GOLD STANDARD)** ‚≠ê‚≠ê‚≠ê\n\n‚Ä¢ Normal: **<50 Œºg/g** dry weight\n\n‚Ä¢ Wilson's: **>250 Œºg/g** dry weight üéØ\n\n‚Ä¢ **MOST SPECIFIC and DEFINITIVE test**\n\n‚Ä¢ **Liver biopsy** with quantitative copper measurement\n\n‚Ä¢ Direct measurement of copper accumulation in **primary affected organ**\n\n**Why it's the BEST:**\n\n‚Üí **Directly measures pathology at source**\n\n‚Üí **Highest sensitivity and specificity**\n\n‚Üí **Not affected by acute phase reactions**\n\n‚Üí **Confirms diagnosis definitively**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã OTHER INVESTIGATIONS (Comparison):\n\n‚Ä¢ **SERUM CERULOPLASMIN:**\n  ‚Üí **Decreased (<20 mg/dL)** in 95% cases\n  ‚Üí Can be **normal in 5%** of Wilson's disease ‚ö†Ô∏è\n  ‚Üí Can be low in other conditions (malnutrition, nephrotic syndrome)\n  ‚Üí Good **screening test** but NOT diagnostic\n\n‚Ä¢ **24-HOUR URINARY COPPER:**\n  ‚Üí **Elevated (>100 Œºg/24hr)**, normal <40\n  ‚Üí Helpful but **not specific**\n  ‚Üí Can be elevated in other cholestatic disorders\n  ‚Üí Good for **monitoring treatment**\n\n‚Ä¢ **KAYSER-FLEISCHER RINGS:**\n  ‚Üí Present in **95% with neurological** Wilson's\n  ‚Üí Only **50% in purely hepatic** cases ‚ö†Ô∏è\n  ‚Üí Detected by **slit-lamp examination**\n  ‚Üí Caused by copper deposition in **Descemet's membrane**\n  ‚Üí Highly specific but **not always present**\n\n‚Ä¢ **MRI BRAIN:**\n  ‚Üí **T2 hyperintensities** in basal ganglia\n  ‚Üí **\"Face of giant panda\" sign** in midbrain\n  ‚Üí Only abnormal in **neurological Wilson's**\n  ‚Üí **Not useful** for early/hepatic disease\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç CLINICAL PRESENTATIONS:\n\n**1. HEPATIC (40-50%):** Age 5-35 years\n   ‚Üí **Acute hepatitis**\n   ‚Üí **Chronic hepatitis** ‚Üí Cirrhosis\n   ‚Üí **Fulminant hepatic failure**\n\n**2. NEUROLOGICAL (40-50%):** Age 20-30 years\n   ‚Üí **Tremors** (wing-beating)\n   ‚Üí **Dysarthria**\n   ‚Üí **Dystonia, rigidity**\n   ‚Üí **Parkinsonism**\n\n**3. PSYCHIATRIC (10-20%):**\n   ‚Üí **Depression**\n   ‚Üí **Personality changes**\n   ‚Üí **Psychosis**\n\n**4. OTHER:**\n   ‚Üí **Hemolytic anemia** (Coombs negative)\n   ‚Üí **Renal tubular acidosis**\n   ‚Üí **Osteoporosis**\n   ‚Üí **Cardiomyopathy**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä TREATMENT:\n\n‚Ä¢ **Copper chelators:**\n  ‚Üí **D-penicillamine** (first-line) ‚≠ê\n  ‚Üí **Trientine** (if intolerant)\n\n‚Ä¢ **Zinc salts** (maintenance therapy)\n\n‚Ä¢ **Low copper diet** (avoid shellfish, nuts, chocolate)\n\n‚Ä¢ **Liver transplant** (fulminant cases)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**HEPATIC COPPER >250 Œºg/g = GOLD STANDARD** ‚≠ê‚≠ê‚≠ê\n\nWhy? Because it **directly measures the PRIMARY pathology** - copper accumulation in the **LIVER**, which is the **FIRST and MOST affected organ** in Wilson's disease.",
    difficulty: "medium",
    imageUrl: "/images/questions/page2_img4.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-9",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Which disease will show the following mode of inheritance?",
    options: [
      "Wiskott",
      "Wilson",
      "Prader-Willi",
      "Achondroplasia"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Wiskott-Aldrich Syndrome (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Wiskott-Aldrich Syndrome (WAS)** is an **X-LINKED RECESSIVE** disorder. The pedigree pattern shows **affected males only**, **carrier females**, and **NO male-to-male transmission**, which is pathognomonic for **X-linked recessive inheritance**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå X-LINKED RECESSIVE INHERITANCE PATTERN:\n\n**CARRIER MOTHER (X^W X) √ó NORMAL FATHER (XY)**\n\n**Offspring:**\n\n‚Ä¢ **25%** - X^W X (Carrier daughter) ‚úì\n‚Ä¢ **25%** - XX (Normal daughter) ‚úì\n‚Ä¢ **25%** - X^W Y (**AFFECTED son**) ‚ö†Ô∏è\n‚Ä¢ **25%** - XY (Normal son) ‚úì\n\n**KEY FEATURES OF X-LINKED RECESSIVE:** ‚≠ê‚≠ê‚≠ê\n\n‚úÖ **Affects MALES predominantly** (hemizygous - only 1 X)\n‚úÖ **Females usually carriers** (heterozygous - 2 X chromosomes)\n‚úÖ **NO male-to-male transmission** (fathers give Y to sons, not X)\n‚úÖ **Affected males from carrier mothers**\n‚úÖ **Can skip generations** (carrier females asymptomatic)\n‚úÖ **Maternal uncles/nephews** affected (classic pattern)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ WISKOTT-ALDRICH SYNDROME (WAS):\n\n**GENETICS:**\n‚Ä¢ **X-linked recessive** (Xp11.23)\n‚Ä¢ **WAS gene** mutation ‚≠ê\n  ‚Üí Encodes **WASP (WAS protein)**\n  ‚Üí WASP regulates **actin cytoskeleton** in hematopoietic cells\n  ‚Üí Defect ‚Üí abnormal platelet and lymphocyte function\n\n**CLASSIC TRIAD:** ‚≠ê‚≠ê‚≠ê\n\n**1. THROMBOCYTOPENIA** (low platelets)\n‚Ä¢ **Small platelets** ‚≠ê‚≠ê‚≠ê (‚Üì MPV - mean platelet volume)\n‚Ä¢ **<70,000/ŒºL** (often <20,000)\n‚Ä¢ Petechiae, purpura, bleeding\n‚Ä¢ **Bloody diarrhea** (common in infancy)\n\n**2. ECZEMA**\n‚Ä¢ Severe atopic dermatitis\n‚Ä¢ Similar to atopic eczema\n‚Ä¢ Pruritic, scaling skin lesions\n\n**3. RECURRENT INFECTIONS**\n‚Ä¢ **Combined immunodeficiency** (B + T cell defects)\n‚Ä¢ **Encapsulated bacteria** (‚Üì IgM, poor polysaccharide response)\n‚Ä¢ **Viral, fungal, opportunistic** infections\n\n**Mnemonic: \"WAITER\"** ‚≠ê\n\n**W** - **Wiskott** (X-linked)\n**A** - **Autoimmunity** (hemolytic anemia, vasculitis)\n**I** - **Infections** (recurrent)\n**T** - **Thrombocytopenia** (**SMALL** platelets!) ‚≠ê‚≠ê‚≠ê\n**E** - **Eczema**\n**R** - **Raised IgE**, **decreased IgM** (‚Üì response to polysaccharides)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**HEMATOLOGIC:**\n‚Ä¢ **Thrombocytopenia** with **SMALL platelets** ‚≠ê‚≠ê‚≠ê (key distinguishing feature!)\n‚Ä¢ **Petechiae, purpura** (often at birth)\n‚Ä¢ **Bloody diarrhea** (infancy)\n‚Ä¢ **Intracranial hemorrhage** (life-threatening)\n\n**IMMUNOLOGIC:**\n‚Ä¢ **Recurrent sinopulmonary infections** (Strep pneumoniae, H. influenzae)\n‚Ä¢ **Opportunistic infections** (PCP, CMV, HSV)\n‚Ä¢ **Progressive T-cell dysfunction**\n‚Ä¢ **‚Üì IgM**, **‚Üë IgE**, **‚Üë IgA**, normal/‚Üì IgG\n\n**DERMATOLOGIC:**\n‚Ä¢ **Severe eczema** (face, flexures)\n‚Ä¢ Similar to atopic dermatitis\n\n**AUTOIMMUNE (30-40%):**\n‚Ä¢ **Autoimmune hemolytic anemia** (AIHA)\n‚Ä¢ **Vasculitis** (especially renal)\n‚Ä¢ **Inflammatory bowel disease**\n‚Ä¢ **Arthritis**\n\n**MALIGNANCY (20%):**\n‚Ä¢ **‚Üë Risk of lymphoma** (EBV-associated)\n‚Ä¢ **Leukemia**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç DIAGNOSIS:\n\n**LABORATORY:**\n\n‚Ä¢ **Thrombocytopenia** (<70,000/ŒºL)\n‚Ä¢ **‚Üì Mean Platelet Volume (MPV)** ‚≠ê‚≠ê‚≠ê **(KEY - platelets SMALL!)**\n‚Ä¢ **‚Üì IgM** (poor response to polysaccharides)\n‚Ä¢ **‚Üë IgE, ‚Üë IgA**\n‚Ä¢ **Lymphopenia** (progressive T-cell decline)\n‚Ä¢ **Poor antibody response** to polysaccharide antigens\n\n**GENETIC:**\n‚Ä¢ **WAS gene sequencing** (confirmatory)\n‚Ä¢ **Flow cytometry:** Absent WASP expression\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**CURATIVE:**\n‚Ä¢ **Hematopoietic stem cell transplant (HSCT)** ‚≠ê‚≠ê‚≠ê **(Only cure!)**\n  ‚Üí Best if done early (before age 5)\n  ‚Üí HLA-matched sibling donor ideal\n  ‚Üí **85-90% cure rate** with matched donor\n\n‚Ä¢ **Gene therapy** (experimental, promising)\n\n**SUPPORTIVE:**\n‚Ä¢ **IVIG** (Intravenous immunoglobulin)\n‚Ä¢ **Prophylactic antibiotics** (PCP prophylaxis with TMP-SMX)\n‚Ä¢ **Splenectomy** (if severe thrombocytopenia - but ‚Üë infection risk!)\n‚Ä¢ **Platelet transfusions** (for bleeding)\n‚Ä¢ **Avoid aspirin, NSAIDs** (worsen bleeding)\n‚Ä¢ **Topical steroids** for eczema\n\n**PROGNOSIS:**\n‚Ä¢ **Without HSCT:** Death usually by age 10-15\n‚Ä¢ **Causes of death:** Bleeding (ICH), infection, malignancy\n‚Ä¢ **With HSCT:** Excellent survival (>85%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã DISEASE COMPARISON (Answer options):\n\n**‚òÖ WISKOTT-ALDRICH** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n‚Ä¢ **Inheritance:** **X-linked Recessive** (XLR)\n‚Ä¢ **Gene:** WAS gene (WASP)\n‚Ä¢ **Clinical:** Thrombocytopenia (**SMALL platelets**) + Eczema + Infections\n‚Ä¢ **Immune:** Combined B+T deficiency\n\n**‚Ä¢ WILSON'S DISEASE** ‚ùå\n\n‚Ä¢ **Inheritance:** **Autosomal Recessive** (AR)\n‚Ä¢ **Gene:** ATP7B (copper transporter)\n‚Ä¢ **Clinical:** Liver disease + neurological (Kayser-Fleischer rings)\n‚Ä¢ **NOT X-linked!**\n\n**‚Ä¢ PRADER-WILLI SYNDROME** ‚ùå\n\n‚Ä¢ **Inheritance:** **Genomic imprinting** (NOT Mendelian)\n‚Ä¢ **Genetics:** **Paternal deletion 15q11-q13** (or maternal UPD 15)\n‚Ä¢ **Clinical:** Hyperphagia, obesity, intellectual disability, hypogonadism\n‚Ä¢ **NOT X-linked!**\n\n**‚Ä¢ ACHONDROPLASIA** ‚ùå\n\n‚Ä¢ **Inheritance:** **Autosomal Dominant** (AD)\n‚Ä¢ **Gene:** **FGFR3** mutation (chromosome 4)\n‚Ä¢ **Clinical:** Short-limb dwarfism, rhizomelic shortening\n‚Ä¢ **NOT X-linked!** (affects both males and females equally)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ OTHER X-LINKED RECESSIVE DISORDERS:\n\n**IMMUNODEFICIENCY:**\n‚Ä¢ **X-linked agammaglobulinemia (Bruton's)** - BTK gene\n‚Ä¢ **X-linked SCID** - IL2RG gene\n‚Ä¢ **Chronic granulomatous disease** (X-linked form) - CYBB gene\n‚Ä¢ **Wiskott-Aldrich** - WAS gene ‚≠ê\n\n**HEMATOLOGIC:**\n‚Ä¢ **Hemophilia A** (Factor VIII deficiency)\n‚Ä¢ **Hemophilia B** (Factor IX deficiency)\n‚Ä¢ **G6PD deficiency**\n\n**NEUROMUSCULAR:**\n‚Ä¢ **Duchenne/Becker muscular dystrophy**\n‚Ä¢ **Fragile X syndrome**\n\n**OTHER:**\n‚Ä¢ **Color blindness** (red-green)\n‚Ä¢ **Hunter syndrome** (MPS II)\n‚Ä¢ **Fabry disease**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**WISKOTT-ALDRICH = X-LINKED RECESSIVE** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"WAS on X: Boys get WASted!\"**\n\n**\"WAITER\" mnemonic:**\n‚Ä¢ **W** - Wiskott (**X-linked**)\n‚Ä¢ **A** - Autoimmunity\n‚Ä¢ **I** - Infections\n‚Ä¢ **T** - **Thrombocytopenia (SMALL platelets!)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **E** - Eczema\n‚Ä¢ **R** - Raised IgE, ‚Üì IgM\n\n**X-linked recessive pattern:**\n‚Ä¢ Affects **MALES** only\n‚Ä¢ **NO male-to-male** transmission\n‚Ä¢ **Carrier females**\n‚Ä¢ **Maternal uncles** affected\n\n**Treatment:** **HSCT = ONLY CURE!**",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-11",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Which is not true?",
    options: [
      "VWD type 1 is mostly severe in children",
      "VWD type 3 is mostly severe in children",
      "VWD type 2 is more related to activity rather than levels",
      "VWD type 3 has severely low VWD"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **\"VWD type 1 is mostly severe in children\" - This is INCORRECT (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Von Willebrand Disease (VWD)** is the **MOST COMMON inherited bleeding disorder** (1-2% of population). The statement \"VWD type 1 is mostly severe\" is **FALSE** - **Type 1 is MILD to MODERATE**, NOT severe!\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå VWD TYPE CLASSIFICATION:\n\n**‚òÖ TYPE 1 (70-80% of VWD)** ‚≠ê‚≠ê‚≠ê **MOST COMMON**\n\n‚Ä¢ **Defect:** **Quantitative** (‚Üì amount, normal function)\n‚Ä¢ **VWF Level:** ‚Üì **30-50%** of normal\n‚Ä¢ **VWF Function:** NORMAL\n‚Ä¢ **Severity:** **MILD to MODERATE** ‚úì (NOT SEVERE! ‚ùå)\n‚Ä¢ **Inheritance:** **Autosomal Dominant** (AD)\n‚Ä¢ **Factor VIII:** Mildly ‚Üì (parallels VWF)\n‚Ä¢ **Clinical:** Mild mucocutaneous bleeding\n‚Ä¢ **Treatment:** **DDAVP** (desmopressin)\n\n**‚Ä¢ TYPE 2 (15-20% of VWD)** - MODERATE\n\n‚Ä¢ **Defect:** **Qualitative** (abnormal function) ‚≠ê\n‚Ä¢ **VWF Level:** Normal or mildly ‚Üì\n‚Ä¢ **VWF Function:** ABNORMAL/DYSFUNCTIONAL\n‚Ä¢ **Key point:** **\"Activity > Levels\"** issue ‚úì (Option C is TRUE!)\n‚Ä¢ **Inheritance:** AD (most subtypes)\n‚Ä¢ **4 Subtypes:**\n  **2A** - ‚Üì high molecular weight multimers\n  **2B** - ‚Üë affinity for GPIb (gain of function)\n  **2M** - ‚Üì platelet binding\n  **2N** - ‚Üì Factor VIII binding (\"Normandy\")\n\n**‚Ä¢ TYPE 3 (1-5% of VWD)** - SEVERE ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è\n\n‚Ä¢ **Defect:** **Complete absence** of VWF\n‚Ä¢ **VWF Level:** **<5%** (virtually absent) ‚úì (Option D is TRUE!)\n‚Ä¢ **Severity:** **SEVERE** in children ‚úì (Option B is TRUE!)\n‚Ä¢ **Inheritance:** **Autosomal Recessive** (AR)\n‚Ä¢ **Factor VIII:** Very LOW (<10%)\n‚Ä¢ **Clinical:** \n  ‚Üí Severe mucocutaneous bleeding\n  ‚Üí **Hemarthrosis** (joint bleeding like hemophilia!)\n  ‚Üí Muscle hematomas\n  ‚Üí Life-threatening bleeding\n‚Ä¢ **Treatment:** VWF/Factor VIII concentrates (DDAVP doesn't work!)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ ANALYSIS OF ALL OPTIONS:\n\n‚ùå **Option A: \"VWD type 1 is mostly severe in children\"**\n\n**INCORRECT! Type 1 is MILD to MODERATE, NOT severe!**\n\n‚Ä¢ Type 1 has **30-50% VWF** (not absent)\n‚Ä¢ Causes **mild mucocutaneous bleeding**\n‚Ä¢ Many patients have **minimal symptoms**\n‚Ä¢ Can go **undiagnosed** for years\n‚Ä¢ **NOT life-threatening** in children\n\n‚úÖ **Option B: \"VWD type 3 is mostly severe in children\"**\n\n**CORRECT!** Type 3 is indeed **SEVERE** in children!\n\n‚Ä¢ **<5% VWF** (virtually absent)\n‚Ä¢ **Early onset** severe bleeding in infancy/childhood\n‚Ä¢ **Life-threatening bleeding** episodes\n‚Ä¢ Requires **prophylactic treatment**\n\n‚úÖ **Option C: \"VWD type 2 is more related to activity rather than levels\"**\n\n**CORRECT!** Type 2 is a **QUALITATIVE defect**!\n\n‚Ä¢ VWF **levels** may be **normal**\n‚Ä¢ VWF **activity** is **decreased** (dysfunctional)\n‚Ä¢ **VWF:RCo/VWF:Ag ratio <0.6** (key diagnostic finding)\n‚Ä¢ The protein is there, but it **doesn't work properly**\n\n‚úÖ **Option D: \"VWD type 3 has severely low VWD\"**\n\n**CORRECT!** Type 3 has **severely low (<5%) or absent VWF**!\n\n‚Ä¢ **Complete or near-complete deficiency**\n‚Ä¢ Both VWF antigen and activity virtually absent\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ VON WILLEBRAND FACTOR (VWF) - FUNCTIONS:\n\n**VWF has 2 CRITICAL roles:**\n\n**1. PRIMARY HEMOSTASIS** ‚≠ê\n\n‚Ä¢ **Platelet ADHESION** to injured endothelium\n‚Ä¢ VWF binds:\n  ‚Üí **Collagen** (exposed on damaged vessel)\n  ‚Üí **GPIb** (glycoprotein Ib on platelets)\n‚Ä¢ Creates **bridge** for platelet plug formation\n\n**2. SECONDARY HEMOSTASIS** ‚≠ê\n\n‚Ä¢ **Carrier protein** for **Factor VIII**\n‚Ä¢ **Protects Factor VIII** from rapid degradation\n‚Ä¢ Increases Factor VIII **half-life** from minutes ‚Üí hours\n‚Ä¢ Without VWF ‚Üí Factor VIII ‚Üì‚Üì‚Üì\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíâ LABORATORY FINDINGS:\n\n**TYPE 1:**\n‚Ä¢ **VWF:Ag:** ‚Üì (30-50%)\n‚Ä¢ **VWF:RCo:** ‚Üì (parallel to antigen)\n‚Ä¢ **Factor VIII:** Mildly ‚Üì\n‚Ä¢ **aPTT:** Normal or mildly ‚Üë\n‚Ä¢ **Bleeding time:** Prolonged\n‚Ä¢ **Platelet count:** Normal\n\n**TYPE 2:**\n‚Ä¢ VWF:Ag: Normal or mildly ‚Üì\n‚Ä¢ **VWF:RCo: ‚Üì‚Üì** (disproportionately low)\n‚Ä¢ **VWF:RCo/VWF:Ag <0.6** ‚≠ê (key finding!)\n‚Ä¢ Multimer analysis: Abnormal pattern\n\n**TYPE 3:**\n‚Ä¢ VWF:Ag: **<5%** (absent)\n‚Ä¢ VWF:RCo: Absent\n‚Ä¢ **Factor VIII: <10%** (very low)\n‚Ä¢ **aPTT:** Markedly prolonged\n‚Ä¢ Bleeding time: Very prolonged\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES BY TYPE:\n\n**TYPE 1 (MILD):**\n‚Ä¢ **Epistaxis** (nosebleeds)\n‚Ä¢ **Easy bruising**\n‚Ä¢ **Menorrhagia** (heavy periods)\n‚Ä¢ Bleeding after dental procedures\n‚Ä¢ **NO hemarthrosis** (joint bleeding)\n‚Ä¢ **PTT:** Normal or slightly ‚Üë\n\n**TYPE 2 (MODERATE):**\n‚Ä¢ **Moderate mucocutaneous bleeding**\n‚Ä¢ **Epistaxis** (++)\n‚Ä¢ **GI bleeding** (can occur)\n‚Ä¢ **Rarely hemarthrosis**\n‚Ä¢ **PTT:** Mildly ‚Üë\n\n**TYPE 3 (SEVERE):**\n‚Ä¢ **Severe mucocutaneous bleeding** (+++)\n‚Ä¢ **Hemarthrosis** ‚≠ê (like hemophilia A/B!)\n‚Ä¢ **Muscle hematomas**\n‚Ä¢ **ICH risk** (intracranial hemorrhage)\n‚Ä¢ **Life-threatening bleeding**\n‚Ä¢ **PTT:** Markedly ‚Üë (Factor VIII ‚Üì‚Üì‚Üì)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**TYPE 1:**\n‚Ä¢ **DDAVP (Desmopressin)** ‚≠ê‚≠ê‚≠ê (1st line)\n  ‚Üí Releases VWF from endothelial stores\n  ‚Üí ‚Üë VWF & Factor VIII by 2-5x\n‚Ä¢ **Tranexamic acid** (antifibrinolytic)\n\n**TYPE 2:**\n‚Ä¢ **DDAVP** (for 2A, 2M, 2N)\n‚Ä¢ **AVOID DDAVP in Type 2B** ‚ö†Ô∏è (causes thrombocytopenia!)\n‚Ä¢ VWF/Factor VIII concentrates\n\n**TYPE 3:**\n‚Ä¢ **VWF/Factor VIII concentrate** (DDAVP doesn't work)\n‚Ä¢ **Prophylaxis** may be needed\n‚Ä¢ Manage like severe hemophilia\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**TYPE 1 = MILD, NOT SEVERE!** ‚≠ê‚≠ê‚≠ê (This is the answer!)\n\n**Remember: \"Type 1 = 1 problem (‚Üì quantity), Type 2 = 2nd problem (‚Üì quality), Type 3 = 3x SEVERE!\"**\n\n‚Ä¢ **Type 1:** 70-80%, **MILD**, Quantitative, AD\n‚Ä¢ **Type 2:** 15-20%, Moderate, **Qualitative (activity issue)**, AD\n‚Ä¢ **Type 3:** 1-5%, **SEVERE**, Absent VWF, AR\n‚Ä¢ **VWF:** Platelet adhesion + Factor VIII carrier",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-14",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A baby failed to pass meconium. The structures absent in the disease are absent in\nwhich layer?",
    options: [
      "Epithelial",
      "Submucosa",
      "Muscular",
      "Serosa"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Submucosa (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Hirschsprung Disease (Congenital Aganglionic Megacolon)** is caused by **absence of ganglion cells** in **BOTH** the **submucosal (Meissner's) plexus** and **myenteric (Auerbach's) plexus**. However, since the question asks which **layer** contains the absent structures, the **submucosa** is the best answer as it's a distinct layer, while the myenteric plexus is located between muscle layers.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå INTESTINAL WALL LAYERS (Inside ‚Üí Outside):\n\n**1. MUCOSA** ‚ùå\n\n‚Ä¢ **Epithelium** (absorptive cells)\n‚Ä¢ **Lamina propria** (connective tissue)\n‚Ä¢ **Muscularis mucosae** (thin smooth muscle)\n‚Ä¢ **In Hirschsprung:** Normal epithelium, NO ganglion cells here\n\n**2. SUBMUCOSA** ‚≠ê‚≠ê‚≠ê **(ANSWER!)**\n\n‚Ä¢ **Connective tissue**\n‚Ä¢ **Blood vessels, lymphatics**\n‚Ä¢ **Meissner's plexus (submucosal plexus)** ‚≠ê‚≠ê‚≠ê\n  ‚Üí **Controls secretion, blood flow**\n  ‚Üí **ABSENT in Hirschsprung!** ‚úó\n  ‚Üí Contains **ganglion cells** normally\n\n**3. MUSCULARIS PROPRIA** ‚ùå\n\n‚Ä¢ **Inner circular muscle layer**\n‚Ä¢ **Auerbach's plexus (myenteric plexus)** ‚≠ê‚≠ê‚≠ê\n  ‚Üí Located **BETWEEN** the muscle layers (not within submucosa)\n  ‚Üí **Controls motility, peristalsis**\n  ‚Üí **ABSENT in Hirschsprung!** ‚úó\n‚Ä¢ **Outer longitudinal muscle layer**\n‚Ä¢ Note: Plexus is between layers, not in \"muscular\" layer itself\n\n**4. SUBSEROSA/SEROSA** ‚ùå\n\n‚Ä¢ **Connective tissue** (subserosa)\n‚Ä¢ **Mesothelium** (serosa)\n‚Ä¢ **In Hirschsprung:** Normal, no ganglion cells here\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ PATHOPHYSIOLOGY:\n\n**EMBRYOLOGY:**\n\n‚Ä¢ **Neural crest cells** migrate from esophagus ‚Üí rectum (5-12 weeks)\n‚Ä¢ Migration is **craniocaudal** (head ‚Üí tail direction)\n‚Ä¢ **Failure of migration** ‚Üí No ganglion cells in distal bowel\n‚Ä¢ **RET proto-oncogene mutation** (most common) ‚≠ê\n\n**NORMAL COLON:**\n\n**Ganglion cells present** ‚úì\n  ‚Üì\n**Coordinated peristalsis**\n  ‚Üì\n**Proximal segment contracts**\n  ‚Üì\n**Distal segment RELAXES** ‚úì\n  ‚Üì\n**Stool passes normally**\n\n**HIRSCHSPRUNG SEGMENT:**\n\n**NO ganglion cells** ‚úó (**Aganglionosis**)\n  ‚Üì\n**Loss of inhibitory innervation**\n  ‚Üì\n**Unopposed sympathetic tone**\n  ‚Üì\n**Distal segment SPASTIC** (always contracted) ‚ö†Ô∏è\n  ‚Üì\n**NO relaxation!** ‚úó\n  ‚Üì\n**Functional obstruction**\n  ‚Üì\n**Proximal colon dilates** (Megacolon)\n  ‚Üì\n**Cannot pass stool!**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**NEONATAL PRESENTATION (Most common):**\n\n‚Ä¢ **Delayed meconium passage >48 hours** ‚≠ê‚≠ê‚≠ê (RED FLAG!)\n  ‚Üí 95% of normal babies pass meconium <48 hrs\n  ‚Üí **90% of Hirschsprung: delayed >48 hrs**\n\n‚Ä¢ **Bilious vomiting**\n‚Ä¢ **Abdominal distension**\n‚Ä¢ **Explosive stool** after rectal exam (relief of obstruction)\n‚Ä¢ **Failure to thrive**\n\n**HIRSCHSPRUNG-ASSOCIATED ENTEROCOLITIS (HAEC):** ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è\n\n‚Ä¢ **Life-threatening complication** (30% of cases)\n‚Ä¢ **Bacterial overgrowth** + ischemia\n‚Ä¢ Presents with:\n  ‚Üí **Explosive, foul-smelling diarrhea**\n  ‚Üí **Fever, toxic appearance**\n  ‚Üí **Abdominal distension, pain**\n  ‚Üí **Sepsis, shock**\n‚Ä¢ **Leading cause of death** in Hirschsprung\n‚Ä¢ **Emergency:** Requires immediate decompression + antibiotics\n\n**OLDER CHILDREN:**\n\n‚Ä¢ **Chronic severe constipation** (from birth)\n‚Ä¢ **Abdominal distension**\n‚Ä¢ **Ribbon-like stools**\n‚Ä¢ **Failure to thrive**\n‚Ä¢ **NO fecal soiling** (vs functional constipation)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìç EXTENT OF INVOLVEMENT:\n\n**SHORT SEGMENT (80%):**\n‚Ä¢ **Rectosigmoid only** (most common) ‚≠ê\n‚Ä¢ Better prognosis\n\n**LONG SEGMENT (15-20%):**\n‚Ä¢ **Beyond sigmoid colon**\n‚Ä¢ More complex surgery\n\n**TOTAL COLONIC (5%):**\n‚Ä¢ **Entire colon** affected\n‚Ä¢ May involve terminal ileum\n‚Ä¢ Worst prognosis\n\n**KEY POINT:** \n‚Ä¢ **ALWAYS involves rectum** (starts distally) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Never \"skips\" rectum (unlike Crohn's)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüîç DIAGNOSIS:\n\n**1. RECTAL BIOPSY** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**\n\n‚Ä¢ **Suction rectal biopsy** (2-3 cm above dentate line)\n\n**Findings:**\n‚Ä¢ **Absence of ganglion cells** in submucosa & myenteric plexus ‚úì\n‚Ä¢ **Hypertrophic nerve fibers**\n‚Ä¢ **‚Üë Acetylcholinesterase (AChE) staining** ‚≠ê (diagnostic!)\n  ‚Üí Positive AChE stain = Hirschsprung confirmed\n\n**2. CONTRAST ENEMA** (Barium enema)\n\n‚Ä¢ **Transition zone** visible ‚≠ê\n  ‚Üí **Narrow distal segment** (aganglionic)\n  ‚Üí **Dilated proximal segment** (normal ganglion cells)\n‚Ä¢ May see **saw-tooth\" irregular mucosa**\n‚Ä¢ **Late films (24h):** Retained contrast in colon\n\n**3. ANORECTAL MANOMETRY**\n\n‚Ä¢ **Absence of rectoanal inhibitory reflex (RAIR)** ‚≠ê\n‚Ä¢ Normal: Rectal distension ‚Üí internal sphincter relaxes\n‚Ä¢ Hirschsprung: **NO relaxation!** (no ganglion cells)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ GENETICS & ASSOCIATIONS:\n\n**GENETICS:**\n‚Ä¢ **RET proto-oncogene** (chromosome 10) - Most common mutation ‚≠ê\n‚Ä¢ **EDNRB** (endothelin receptor B)\n‚Ä¢ **Male:Female = 4:1**\n‚Ä¢ **Familial risk:** ~4% sibling recurrence\n\n**ASSOCIATED CONDITIONS:**\n‚Ä¢ **Down syndrome (Trisomy 21)** ‚≠ê (10-15% of HD patients)\n‚Ä¢ **MEN 2A, MEN 2B** (RET mutations)\n‚Ä¢ **Waardenburg syndrome** (hearing loss, heterochromia)\n‚Ä¢ **Congenital central hypoventilation (Ondine's curse)**\n‚Ä¢ **Cardiac defects** (VSD, ASD)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**INITIAL MANAGEMENT:**\n\n‚Ä¢ **NPO** (nothing by mouth)\n‚Ä¢ **NG tube decompression**\n‚Ä¢ **IV fluids**\n‚Ä¢ **Rectal irrigations** (decompress bowel)\n‚Ä¢ **Antibiotics** (if enterocolitis suspected)\n\n**DEFINITIVE TREATMENT:** **SURGERY** ‚≠ê\n\n‚Ä¢ **Pull-through procedures:**\n  ‚Üí **Swenson** (original)\n  ‚Üí **Duhamel** (most common)\n  ‚Üí **Soave** (endorectal)\n\n‚Ä¢ **Principle:** Resect aganglionic segment + anastomose normal bowel to anus\n\n‚Ä¢ **Timing:** \n  ‚Üí Can be done in **infancy** (single-stage)\n  ‚Üí Or **delayed** with temporary colostomy\n\n**PROGNOSIS:**\n‚Ä¢ **85-90%** have good bowel function\n‚Ä¢ **Persistent constipation** (25%)\n‚Ä¢ **Fecal incontinence** (10-15%)\n‚Ä¢ **Recurrent enterocolitis** (5-10%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINTS FOR EXAM:\n\n**HIRSCHSPRUNG = NO GANGLION IN SUBMUCOSA** ‚≠ê‚≠ê‚≠ê\n\n**Remember: \"HD = Hasn't Defecated (>48hrs)\"**\n\n‚Ä¢ **Delayed meconium >48 hrs** = RED FLAG!\n‚Ä¢ **Absence of ganglion cells** in **Meissner's (submucosa)** + **Auerbach's (myenteric) plexus**\n‚Ä¢ **ALWAYS involves rectum** (starts distally)\n‚Ä¢ **Diagnosis:** Rectal biopsy (‚Üë AChE stain, no ganglion cells)\n‚Ä¢ **Contrast enema:** Transition zone\n‚Ä¢ **Anorectal manometry:** No RAIR\n‚Ä¢ **RET gene mutation** (most common)\n‚Ä¢ **Association:** Down syndrome (10-15%)\n‚Ä¢ **Complication:** HAEC (enterocolitis) - life-threatening!\n‚Ä¢ **Treatment:** Surgical pull-through",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-16",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient presented to the eye OPD after 3 years of cataract surgery. Slit lamp\nfinding was given. What is the likely diagnosis?",
    options: [
      "PCO",
      "Bullous keratopathy",
      "Phakic glaucoma",
      "Lens subluxation"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **PCO - Posterior Capsule Opacification (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Posterior Capsule Opacification (PCO)**, also called **\"secondary cataract\"** or **\"after-cataract\"**, is the **MOST COMMON long-term complication** following cataract surgery.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå PATHOPHYSIOLOGY OF PCO:\n\n**NORMAL CATARACT SURGERY:**\n\n**1. Phacoemulsification** ‚≠ê\n   ‚Üí **Removes cloudy lens nucleus and cortex**\n   ‚Üí **Preserves posterior capsule** (kept intact)\n   ‚Üí **IOL (Intraocular Lens)** placed in capsular bag\n\n**2. RESIDUAL LENS EPITHELIAL CELLS (LECs)**\n   ‚Üí Some LECs remain at **equator** of capsular bag\n   ‚Üí Normally quiescent after surgery\n\n**3. PCO DEVELOPMENT** (months to years later)\n\n**LECs proliferate** ‚Üí Migrate posteriorly ‚Üí Cover posterior capsule\n\n   ‚Üì\n\n**Two types of changes:**\n\n‚Ä¢ **Fibrotic PCO (pearl type)** ‚≠ê‚≠ê‚≠ê\n  ‚Üí LECs undergo **Elschnig pearl formation**\n  ‚Üí Bladder-like cells with aberrant lens fiber differentiation\n  ‚Üí **Most common** type\n  ‚Üí Dense white opacification\n\n‚Ä¢ **Fibrous PCO (fibrosis type)**\n  ‚Üí LECs undergo **epithelial-mesenchymal transition (EMT)**\n  ‚Üí Myofibroblast formation\n  ‚Üí **Capsular wrinkling** and contraction\n\n   ‚Üì\n\n**POSTERIOR CAPSULE OPACITY** ‚Üí Blocks light\n\n   ‚Üì\n\n**GRADUAL VISION LOSS** (similar to original cataract)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**TIMELINE:**\n\n‚Ä¢ Can occur **months to years** after surgery\n‚Ä¢ This patient: **3 years post-op** ‚úì\n‚Ä¢ **30-50%** of patients within 2-5 years\n\n**SYMPTOMS:**\n\n‚Ä¢ **Gradual, progressive vision loss** ‚≠ê\n‚Ä¢ **Glare** and **halos** around lights\n‚Ä¢ Difficulty with **night driving**\n‚Ä¢ **Reduced contrast sensitivity**\n‚Ä¢ Feels like \"cataract has returned\"\n\n**SLIT LAMP FINDINGS:**\n\n‚Ä¢ **White/pearl-like opacity** on posterior capsule ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Elschnig pearls** (bladder cells)\n‚Ä¢ **Capsular wrinkling** (if fibrotic)\n‚Ä¢ **IOL visible** through opacity\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä TREATMENT: **Nd:YAG LASER CAPSULOTOMY** ‚≠ê‚≠ê‚≠ê\n\n**PROCEDURE:**\n\n‚Ä¢ **Neodymium:YAG laser** (1064 nm wavelength)\n‚Ä¢ **Photodisruption** of posterior capsule\n‚Ä¢ Creates **central opening** in opacified capsule\n‚Ä¢ **Outpatient procedure**, 5-10 minutes\n‚Ä¢ **Immediate** vision improvement\n\n**ADVANTAGES:**\n\n‚úÖ **Non-invasive** (no incision)\n‚úÖ **Painless** (topical anesthesia)\n‚úÖ **Quick** procedure\n‚úÖ **High success rate** (>95%)\n‚úÖ **Immediate visual recovery**\n\n**COMPLICATIONS** (rare):\n\n‚Ä¢ **Retinal detachment** (0.5-2%) ‚ö†Ô∏è\n‚Ä¢ **Cystoid macular edema**\n‚Ä¢ **IOL damage/pitting**\n‚Ä¢ **Increased IOP** (transient)\n‚Ä¢ **Vitreous prolapse**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Bullous Keratopathy** ‚ùå\n\n‚Ä¢ **Corneal endothelial** dysfunction\n‚Ä¢ Presents with **corneal edema**, **painful eye**\n‚Ä¢ **Epithelial bullae** visible\n‚Ä¢ Occurs **early** post-op (not 3 years)\n‚Ä¢ Causes **corneal haze**, not posterior capsule opacity\n\n**C. Phakic Glaucoma** ‚ùå\n\n‚Ä¢ Not applicable: patient is **pseudophakic** (IOL present)\n‚Ä¢ **Phakic** = natural lens present\n‚Ä¢ After cataract surgery = **pseudophakic**\n‚Ä¢ Wrong terminology\n\n**D. Lens Subluxation** ‚ùå\n\n‚Ä¢ **Zonular weakness** causing lens displacement\n‚Ä¢ **NOT relevant** after cataract extraction\n‚Ä¢ Natural lens already removed\n‚Ä¢ **IOL dislocation** is possible but presents differently\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ RISK FACTORS FOR PCO:\n\n**HIGH RISK:**\n\n‚Ä¢ **Young age** (<50 years) ‚≠ê\n‚Ä¢ **Diabetes mellitus**\n‚Ä¢ **Uveitis**\n‚Ä¢ **Myopia**\n‚Ä¢ **Incomplete cortical cleanup** during surgery\n\n**PROTECTIVE FACTORS:**\n\n‚Ä¢ **Sharp-edged IOL** (square edge design) ‚≠ê\n‚Ä¢ **Hydrophobic acrylic IOL**\n‚Ä¢ **Complete cortical cleanup**\n‚Ä¢ **In-the-bag IOL placement**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**PCO = MOST COMMON LONG-TERM complication after cataract surgery** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**P**earls **C**loud **O**ver\" the capsule!\n\n‚Ä¢ **Timeline:** Months to years post-op\n‚Ä¢ **Cause:** Lens epithelial cell proliferation\n‚Ä¢ **Appearance:** White/pearl opacity on posterior capsule\n‚Ä¢ **Treatment:** **Nd:YAG laser capsulotomy** (definitive)\n‚Ä¢ **Outcome:** Excellent (>95% success, immediate improvement)",
    difficulty: "medium",
    imageUrl: "/images/questions/page5_img10.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-18",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient came with nyctalopia. Rational image given below, what will be the\ndiagnosis?",
    options: [
      "Retinitis pigmentosa",
      "Vitamin A deficiency",
      "Retinal detachment",
      "Diabetic retinopathy"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Retinitis Pigmentosa (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Retinitis Pigmentosa (RP)** is a group of **inherited retinal dystrophies** characterized by **progressive degeneration of photoreceptors** (rods and cones), leading to **blindness**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå PATHOPHYSIOLOGY:\n\n**NORMAL RETINAL ANATOMY:**\n\n‚Ä¢ **Photoreceptors:**\n  ‚Üí **Rods** (120 million) - peripheral retina, night vision, motion\n  ‚Üí **Cones** (6 million) - central retina (macula), color, acuity\n\n‚Ä¢ **Rod function** = **scotopic vision** (dim light, night vision) ‚≠ê\n‚Ä¢ **Cone function** = **photopic vision** (bright light, color)\n\n**RETINITIS PIGMENTOSA:**\n\n**PRIMARY DEFECT:**\n\n‚Ä¢ **Genetic mutations** in >100 genes (rhodopsin, peripherin, etc.)\n‚Ä¢ **Rods affected FIRST** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Progressive rod degeneration ‚Üí **nyctalopia** (night blindness)\n‚Ä¢ **Cones degenerate later** ‚Üí central vision loss\n\n**PROGRESSION SEQUENCE:**\n\n**1. EARLY STAGE** (childhood/adolescence)\n   ‚Üí **Nyctalopia** (night blindness) ‚≠ê‚≠ê‚≠ê **FIRST SYMPTOM**\n   ‚Üí Difficulty navigating in dim light\n   ‚Üí Trouble with dark adaptation\n\n**2. MIDDLE STAGE** (20s-30s)\n   ‚Üí **Peripheral visual field loss** (\"tunnel vision\")\n   ‚Üí **Ring scotoma** at mid-periphery\n   ‚Üí Central vision still preserved\n\n**3. LATE STAGE** (40s-50s)\n   ‚Üí **Cone involvement** ‚Üí central vision loss\n   ‚Üí **Legal blindness**\n   ‚Üí May retain small central island\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**SYMPTOMS:**\n\n‚Ä¢ **Nyctalopia (night blindness)** ‚≠ê‚≠ê‚≠ê **HALLMARK**\n  ‚Üí First and most prominent symptom\n  ‚Üí Difficulty seeing in dark/dim environments\n  ‚Üí Poor dark adaptation\n\n‚Ä¢ **Progressive peripheral vision loss**\n  ‚Üí **\"Tunnel vision\"**\n  ‚Üí Difficulty with mobility\n  ‚Üí Frequent stumbling/bumping into objects\n\n‚Ä¢ **Late:** Central vision loss, color vision loss\n\n**FUNDOSCOPY FINDINGS** (Classic Triad):\n\n**1. \"Bone-spicule\" pigmentation** ‚≠ê‚≠ê‚≠ê\n   ‚Üí **Pathognomonic** finding\n   ‚Üí Black pigment clumps in mid-periphery\n   ‚Üí Looks like \"bone spicules\" or \"spider legs\"\n   ‚Üí Result of **RPE migration** and degeneration\n\n**2. Attenuated retinal vessels** ‚≠ê\n   ‚Üí **Narrowed arterioles**\n   ‚Üí \"Thread-like\" appearance\n   ‚Üí Due to reduced metabolic demand\n\n**3. Waxy pallor of optic disc** ‚≠ê\n   ‚Üí **Optic atrophy**\n   ‚Üí Pale, waxy appearance\n   ‚Üí Secondary to photoreceptor loss\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüß¨ GENETICS & INHERITANCE:\n\n‚Ä¢ **Autosomal Dominant** (30-40%) - least severe\n‚Ä¢ **Autosomal Recessive** (50-60%) - most common\n‚Ä¢ **X-linked** (5-15%) - most severe, males affected\n‚Ä¢ **Mitochondrial** (rare)\n\n**Common genes:**\n‚Ä¢ **Rhodopsin** (RHO) - most common AD\n‚Ä¢ **USH2A** - most common AR\n‚Ä¢ **RPGR** - most common X-linked\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Vitamin A Deficiency** ‚ùå\n\n‚Ä¢ Also causes **nyctalopia**, BUT:\n  ‚Üí **Bitot's spots** (conjunctival foam)\n  ‚Üí **Xerophthalmia** (dry eyes)\n  ‚Üí **Keratomalacia** (corneal softening)\n  ‚Üí **NO bone-spicule pigmentation** ‚ö†Ô∏è\n  ‚Üí **Reversible** with vitamin A\n‚Ä¢ Fundoscopy shows **normal retina** initially\n\n**C. Retinal Detachment** ‚ùå\n\n‚Ä¢ **Sudden**, not gradual\n‚Ä¢ **Flashes** (photopsia) and **floaters**\n‚Ä¢ **Curtain-like** visual field defect\n‚Ä¢ **Different fundoscopy:** elevated retina, tears\n‚Ä¢ **NO nyctalopia as presenting symptom**\n\n**D. Diabetic Retinopathy** ‚ùå\n\n‚Ä¢ **Microaneurysms**, **hemorrhages**, **exudates**\n‚Ä¢ **NO bone-spicule pigmentation**\n‚Ä¢ **Macular edema** common\n‚Ä¢ Central vision affected (not peripheral first)\n‚Ä¢ **No night blindness** as primary symptom\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ INVESTIGATIONS:\n\n‚Ä¢ **Electroretinogram (ERG)** ‚≠ê‚≠ê‚≠ê **DIAGNOSTIC**\n  ‚Üí **Severely reduced** or **absent** responses\n  ‚Üí **Rod responses** affected first\n  ‚Üí **Gold standard** for diagnosis\n\n‚Ä¢ **Visual Field Testing**\n  ‚Üí **Ring scotoma** (mid-peripheral)\n  ‚Üí Progressive constriction (\"tunnel vision\")\n\n‚Ä¢ **Fundus Autofluorescence**\n  ‚Üí Shows areas of RPE atrophy\n\n‚Ä¢ **OCT** (Optical Coherence Tomography)\n  ‚Üí Thinning of photoreceptor layer\n  ‚Üí Loss of outer retinal architecture\n\n‚Ä¢ **Genetic Testing**\n  ‚Üí Identifies specific mutation\n  ‚Üí Guides prognosis and genetic counseling\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**NO CURE** currently ‚ö†Ô∏è\n\n**SUPPORTIVE:**\n\n‚Ä¢ **Vitamin A palmitate** (15,000 IU/day)\n  ‚Üí May slow progression slightly\n  ‚Üí Controversial benefit\n\n‚Ä¢ **Low vision aids**\n  ‚Üí Magnifiers, telescopes\n  ‚Üí Night vision devices\n\n‚Ä¢ **Genetic counseling**\n‚Ä¢ **Treat complications:** cataract (common), CME\n\n**EMERGING THERAPIES:**\n\n‚Ä¢ **Gene therapy** (Luxturna for RPE65 mutations)\n‚Ä¢ **Retinal prosthesis** (\"Argus II\" bionic eye)\n‚Ä¢ **Stem cell therapy** (experimental)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Retinitis Pigmentosa = Night Blindness + Bone Spicules + Tunnel Vision** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**R**ods **P**erish first ‚Üí **N**ight blindness!\"\n\n‚Ä¢ **First symptom:** Nyctalopia (night blindness)\n‚Ä¢ **Pathognomonic:** Bone-spicule pigmentation\n‚Ä¢ **Progression:** Rods (peripheral) ‚Üí Cones (central)\n‚Ä¢ **ERG:** Diagnostic (reduced/absent)\n‚Ä¢ **Genetics:** Multiple inheritance patterns (AD, AR, X-linked)",
    difficulty: "medium",
    imageUrl: "/images/questions/page6_img13.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-19",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Patient was shown image A along with image B. Image C was visualised. What is\nthe likely diagnosis?",
    options: [
      "Left eye suppression",
      "Right eye suppression",
      "Crossed diplopia",
      "Uncrossed diplopia"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Right eye suppression (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Binocular vision suppression** is a **neurological adaptation** where the brain actively **ignores (suppresses)** visual input from one eye to avoid **diplopia (double vision)**.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå NORMAL BINOCULAR VISION:\n\n‚Ä¢ **Both eyes** send images to visual cortex\n‚Ä¢ Brain **fuses** the two images ‚Üí **Single 3D image**\n‚Ä¢ **Stereopsis** (depth perception) achieved\n‚Ä¢ **Binocular single vision (BSV)** maintained\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ SUPPRESSION MECHANISM:\n\n**WHEN DOES IT OCCUR?**\n\n**1. STRABISMUS (Squint)** ‚≠ê‚≠ê‚≠ê **Most Common**\n\n‚Ä¢ **Misalignment** of eyes\n‚Ä¢ Each eye sends **different image**\n‚Ä¢ Brain cannot fuse ‚Üí **Diplopia**\n‚Ä¢ To avoid confusion, brain **suppresses** one eye ‚≠ê\n\n**2. ANISOMETROPIA**\n\n‚Ä¢ **Different refractive errors** between eyes\n‚Ä¢ One eye sees **clear**, other **blurred**\n‚Ä¢ Brain favors **clearer image**, suppresses blurred\n\n**3. AMBLYOPIA (Lazy Eye)**\n\n‚Ä¢ **Poor visual development** in one eye\n‚Ä¢ Brain prefers **better-seeing eye**\n‚Ä¢ Suppresses amblyopic eye input\n\n**4. MEDIA OPACITY**\n\n‚Ä¢ **Cataract, corneal scar** in one eye\n‚Ä¢ Reduced image quality\n‚Ä¢ Brain suppresses degraded input\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ TYPES OF SUPPRESSION:\n\n**1. CONSTANT SUPPRESSION** ‚ö†Ô∏è\n\n‚Ä¢ **Same eye** always suppressed\n‚Ä¢ **High risk** of amblyopia\n‚Ä¢ Needs urgent treatment\n‚Ä¢ Common in **unilateral strabismus**\n\n**2. ALTERNATING SUPPRESSION** ‚úì\n\n‚Ä¢ **Switches** between eyes\n‚Ä¢ **Lower risk** of amblyopia\n‚Ä¢ Both eyes maintain some function\n‚Ä¢ Common in **alternating strabismus**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã CLINICAL TESTING:\n\n**WORTH 4-DOT TEST** ‚≠ê‚≠ê‚≠ê (Most likely this question's test)\n\n**SETUP:**\n‚Ä¢ Patient wears **red-green glasses**\n‚Ä¢ Views **4 dots**: 1 red, 2 green, 1 white\n‚Ä¢ **Red filter** on right eye, **green** on left\n\n**INTERPRETATION:**\n\n‚Ä¢ **Normal (4 dots):** Red, 2 green, white = BSV present ‚úì\n\n‚Ä¢ **Right eye suppression (2 dots):** ‚≠ê‚≠ê‚≠ê **(THIS QUESTION)**\n  ‚Üí Sees only **2 GREEN dots**\n  ‚Üí Red filter suppressed\n  ‚Üí **Right eye not contributing**\n\n‚Ä¢ **Left eye suppression (3 dots):**\n  ‚Üí Sees **1 red + 1 white + 1 red-white**\n  ‚Üí Green filter suppressed\n\n‚Ä¢ **Diplopia (5 dots):**\n  ‚Üí Sees **both images separately**\n  ‚Üí No fusion, no suppression\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Left eye suppression** ‚ùå\n\n‚Ä¢ Would show **3 dots** (red dominant)\n‚Ä¢ Patient sees **green dominant** ‚Üí Right suppressed\n\n**C. Crossed diplopia** ‚ùå\n\n‚Ä¢ **Esotropia** (eyes turned in)\n‚Ä¢ **5 dots visible** (both images seen)\n‚Ä¢ Red dot on **left**, green on **right**\n‚Ä¢ No suppression present\n\n**D. Uncrossed diplopia** ‚ùå\n\n‚Ä¢ **Exotropia** (eyes turned out)\n‚Ä¢ **5 dots visible** (both images seen)\n‚Ä¢ Red dot on **right**, green on **left**\n‚Ä¢ No suppression present\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ö†Ô∏è CLINICAL SIGNIFICANCE:\n\n**CONSEQUENCES OF SUPPRESSION:**\n\n‚Ä¢ **Loss of binocular vision**\n‚Ä¢ **Loss of stereopsis** (depth perception)\n‚Ä¢ **Risk of amblyopia** (if constant)\n‚Ä¢ **Permanent visual impairment** (if untreated in children)\n\n**CRITICAL AGE:**\n\n‚Ä¢ **Sensitive period:** Birth to **8-9 years** ‚≠ê\n‚Ä¢ Treatment **MUST** be before age 8\n‚Ä¢ After this, suppression becomes **permanent**\n‚Ä¢ Amblyopia **irreversible** after sensitive period\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**1. TREAT UNDERLYING CAUSE:**\n\n‚Ä¢ **Refractive correction** (glasses)\n‚Ä¢ **Strabismus surgery** (align eyes)\n‚Ä¢ **Cataract removal** (clear media)\n\n**2. OCCLUSION THERAPY:**\n\n‚Ä¢ **Patch good eye** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ Forces brain to use suppressed eye\n‚Ä¢ Stimulates visual development\n‚Ä¢ **2-6 hours/day** depending on age\n\n**3. PENALIZATION:**\n\n‚Ä¢ **Atropine drops** in good eye\n‚Ä¢ Blurs near vision\n‚Ä¢ Alternative to patching\n\n**4. VISION THERAPY:**\n\n‚Ä¢ Exercises to improve binocular function\n‚Ä¢ Orthoptic exercises\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Suppression = Brain's way to avoid diplopia in strabismus** ‚≠ê‚≠ê‚≠ê\n\n**Worth 4-Dot Test:**\n‚Ä¢ **2 dots** = Right eye suppression (green seen only)\n‚Ä¢ **3 dots** = Left eye suppression (red seen)\n‚Ä¢ **4 dots** = Normal binocular vision\n‚Ä¢ **5 dots** = Diplopia (no suppression)\n\n**Remember:** \"**S**uppression **S**aves from **S**eeing double (diplopia)!\"\n\n‚Ä¢ Protective mechanism but risks amblyopia\n‚Ä¢ Treat urgently in children (<8 years)\n‚Ä¢ Patch therapy forces suppressed eye to work",
    difficulty: "medium",
    imageUrl: "/images/questions/page6_img14.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-20",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient presents in the eye OPD with this finding. What is the diagnosis?",
    options: [
      "Dermoid",
      "Lipodermoid",
      "Pterygium",
      "Papilloma"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Dermoid (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Limbal dermoid** is a **congenital choristoma** (normal tissue in abnormal location) containing **ectodermal and mesodermal elements** at the corneoscleral limbus.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå DERMOID vs LIPODERMOID:\n\n**DERMOID CYST/TUMOR** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**LOCATION:**\n‚Ä¢ **Inferotemporal limbus** (most common) ‚≠ê\n‚Ä¢ Junction of cornea and sclera\n‚Ä¢ Can extend into cornea or sclera\n\n**APPEARANCE:**\n‚Ä¢ **Solid**, round, **white-yellowish** mass\n‚Ä¢ **Hair may be visible** on surface ‚≠ê\n‚Ä¢ Smooth surface\n‚Ä¢ **Well-defined margins**\n‚Ä¢ Size: **3-10 mm**\n\n**HISTOLOGY:**\n‚Ä¢ **Keratinized epithelium** (skin-like) ‚≠ê\n‚Ä¢ **Sebaceous glands**\n‚Ä¢ **Hair follicles** ‚≠ê\n‚Ä¢ **Adipose tissue**\n‚Ä¢ Connective tissue\n\n**ASSOCIATIONS:**\n‚Ä¢ **Goldenhar syndrome** ‚≠ê‚≠ê‚≠ê (Oculo-auriculo-vertebral spectrum)\n  ‚Üí Facial asymmetry\n  ‚Üí Preauricular tags\n  ‚Üí Vertebral abnormalities\n‚Ä¢ Usually **sporadic**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL FEATURES:\n\n**PRESENTATION:**\n\n‚Ä¢ **Present since birth** ‚≠ê\n‚Ä¢ **Non-progressive** (grows with child)\n‚Ä¢ **Asymptomatic** usually\n‚Ä¢ **Cosmetic concern**\n‚Ä¢ May cause **astigmatism** (if large, distorts cornea)\n‚Ä¢ **No inflammation** typically\n\n**SYMPTOMS (if any):**\n‚Ä¢ Foreign body sensation\n‚Ä¢ Irritation\n‚Ä¢ Visual impairment (if obscures visual axis)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Lipodermoid** ‚ùå\n\n**DIFFERENT location and appearance:**\n\n‚Ä¢ Location: **Superotemporal fornix** (NOT limbus) ‚ö†Ô∏è\n‚Ä¢ **Soft, mobile, yellow** mass\n‚Ä¢ Under upper eyelid (hidden)\n‚Ä¢ **Moves with eye movements**\n‚Ä¢ **Contains mostly FAT** (not hair/glands)\n‚Ä¢ Smooth, glistening surface\n\n**C. Pterygium** ‚ùå\n\n‚Ä¢ **Fibrovascular growth** (NOT congenital)\n‚Ä¢ **Nasal side** (99%) ‚Üí crosses onto cornea\n‚Ä¢ **Triangular shape** with apex toward cornea ‚≠ê\n‚Ä¢ **Vascularized** (pink/red color)\n‚Ä¢ **Acquired** (UV exposure, dust)\n‚Ä¢ **Progressive** (grows over time)\n‚Ä¢ Age: adults, not congenital\n\n**D. Papilloma** ‚ùå\n\n‚Ä¢ **Conjunctival growth** (NOT limbal)\n‚Ä¢ **Pedunculated** (stalk-like) ‚≠ê\n‚Ä¢ **Pink/red color** (vascular)\n‚Ä¢ **Cauliflower/raspberry appearance**\n‚Ä¢ **HPV-associated** (viral)\n‚Ä¢ Can be multiple\n‚Ä¢ NOT congenital\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIFFERENTIAL DIAGNOSIS:\n\n| Feature | Dermoid | Lipodermoid | Pterygium |\n|---------|---------|-------------|----------|\n| **Location** | Inferotemporal **limbus** | Superotemporal **fornix** | **Nasal** limbus |\n| **Onset** | **Congenital** | **Congenital** | **Acquired** |\n| **Color** | **White-yellow** | **Yellow** | **Pink-red** |\n| **Hair** | **May have** ‚úì | **No** | **No** |\n| **Mobility** | Fixed | **Mobile** | Fixed |\n| **Growth** | Non-progressive | Non-progressive | **Progressive** |\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**INDICATIONS FOR SURGERY:**\n\n‚Ä¢ **Cosmetic concerns** (most common reason)\n‚Ä¢ **Visual axis obstruction**\n‚Ä¢ **Significant astigmatism**\n‚Ä¢ **Increasing size**\n\n**SURGICAL TECHNIQUE:**\n\n‚Ä¢ **Excisional keratectomy** ‚≠ê\n‚Ä¢ **Lamellar dissection** (partial thickness)\n‚Ä¢ **Amniotic membrane graft** (if deep)\n‚Ä¢ **Conjunctival autograft** (if large defect)\n\n**TIMING:**\n\n‚Ä¢ Can be done **any age** if needed\n‚Ä¢ Usually wait until **2-3 years** (unless urgent)\n‚Ä¢ Better surgical cooperation in older children\n\n**COMPLICATIONS:**\n\n‚Ä¢ **Corneal scarring** (if deep excision)\n‚Ä¢ **Astigmatism** (postoperative)\n‚Ä¢ **Recurrence** (rare, <5%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Limbal Dermoid = Congenital + Inferotemporal + White-yellow + Hair** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**D**ermoid has **D**ander (hair)!\"\n\n‚Ä¢ **Location:** Inferotemporal limbus ‚≠ê\n‚Ä¢ **Congenital** choristoma (present at birth)\n‚Ä¢ **Solid** mass with possible **hair** on surface\n‚Ä¢ Associated with **Goldenhar syndrome**\n‚Ä¢ Treatment: **Surgical excision** (if symptomatic/cosmetic)",
    difficulty: "medium",
    imageUrl: "/images/questions/page7_img16.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-21",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In Wilson‚Äôs disease, the best choice of investigation is?",
    options: [
      "Serum copper",
      "Ceruloplasmin",
      "Hepatic copper estimation",
      "Urine copper"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Ceruloplasmin (Option B)** - But note: **Hepatic copper is GOLD STANDARD**\n\nüî¨ DETAILED EXPLANATION:\n\n**Wilson's disease** requires multiple investigations. While **hepatic copper** is the **GOLD STANDARD** (as explained in Q2), **serum ceruloplasmin** is the **BEST SCREENING TEST** and most commonly used initial investigation.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå DIAGNOSTIC APPROACH IN WILSON'S DISEASE:\n\n**FIRST-LINE INVESTIGATIONS** (Screening):\n\n**1. SERUM CERULOPLASMIN** ‚≠ê‚≠ê‚≠ê **(MOST PRACTICAL ANSWER)**\n\n**Why it's commonly the \"best choice\":**\n‚Ä¢ **Non-invasive** (simple blood test)\n‚Ä¢ **Widely available**\n‚Ä¢ **Inexpensive**\n‚Ä¢ **Good screening test**\n‚Ä¢ **Low in 95%** of Wilson's cases\n\n**NORMAL:** 20-40 mg/dL\n\n**WILSON'S:** **<20 mg/dL** ‚≠ê‚≠ê‚≠ê\n\n**LIMITATIONS:** ‚ö†Ô∏è\n‚Ä¢ **Can be normal** in 5% of Wilson's patients\n‚Ä¢ **Also low** in: Malnutrition, nephrotic syndrome, protein-losing enteropathy\n‚Ä¢ **Can be elevated** as acute phase reactant (infection, inflammation)\n‚Ä¢ **NOT diagnostic alone** - needs confirmation\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ COMPLETE DIAGNOSTIC WORKUP:\n\n**SCREENING TESTS:**\n\n**1. Serum Ceruloplasmin** ‚≠ê **(Best initial test)**\n‚Ä¢ Low (<20 mg/dL) in 95%\n‚Ä¢ Quick, non-invasive\n\n**2. 24-Hour Urinary Copper** ‚≠ê\n‚Ä¢ **Elevated (>100 Œºg/24hr)** in Wilson's\n‚Ä¢ Normal: <40 Œºg/24hr\n‚Ä¢ Good for monitoring treatment\n\n**3. Slit-Lamp Examination** ‚≠ê\n‚Ä¢ **Kayser-Fleischer (KF) rings**\n‚Ä¢ Present in 95% with neurological symptoms\n‚Ä¢ Only 50% in purely hepatic cases\n‚Ä¢ **Highly specific** when present\n\n**CONFIRMATORY TEST:**\n\n**4. HEPATIC COPPER CONTENT** ‚≠ê‚≠ê‚≠ê **(GOLD STANDARD)**\n‚Ä¢ **Liver biopsy** with quantitative copper measurement\n‚Ä¢ **>250 Œºg/g dry weight** = diagnostic\n‚Ä¢ Normal: <50 Œºg/g\n‚Ä¢ **Most specific and definitive**\n‚Ä¢ Invasive, so done after screening tests\n\n**OTHER TESTS:**\n\n**5. Genetic Testing**\n‚Ä¢ **ATP7B gene** sequencing\n‚Ä¢ Confirmatory\n‚Ä¢ Useful for family screening\n\n**6. Liver Function Tests**\n‚Ä¢ Transaminases elevated\n‚Ä¢ Albumin, PT/INR abnormal\n\n**7. MRI Brain** (if neurological)\n‚Ä¢ T2 hyperintensities in basal ganglia\n‚Ä¢ \"Face of giant panda\" sign\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã COMPARISON OF INVESTIGATIONS:\n\n| Investigation | Sensitivity | Specificity | Invasive? | Cost |\n|---------------|-------------|-------------|-----------|------|\n| **Ceruloplasmin** | 95% | Moderate | No ‚úì | Low |\n| **Urinary copper** | High | Moderate | No ‚úì | Low |\n| **KF rings** | 50-95% | Very High | No ‚úì | Low |\n| **Hepatic copper** ‚≠ê | 100% | **Very High** | **Yes** | High |\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE LESS IDEAL:\n\n**A. Serum Copper** ‚ùå\n\n‚Ä¢ **Usually LOW** in Wilson's (paradoxically)\n‚Ä¢ But **most copper bound to ceruloplasmin**\n‚Ä¢ **Free (non-ceruloplasmin) copper** is actually elevated\n‚Ä¢ **Not routinely measured**\n‚Ä¢ **Less reliable** than ceruloplasmin\n\n**C. Hepatic copper estimation** \n\n‚Ä¢ This is actually the **GOLD STANDARD** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Most definitive test**\n‚Ä¢ But **invasive** (liver biopsy required)\n‚Ä¢ Done **after** screening tests suggest Wilson's\n‚Ä¢ Not the **first choice** due to invasiveness\n‚Ä¢ If question asks \"gold standard\" ‚Üí Choose this!\n‚Ä¢ If question asks \"best screening\" ‚Üí Choose ceruloplasmin\n\n**D. Urine copper**\n\n‚Ä¢ **Also elevated** in Wilson's (>100 Œºg/24hr)\n‚Ä¢ Good for diagnosis and monitoring\n‚Ä¢ But **ceruloplasmin is preferred** for initial screening\n‚Ä¢ Urine copper used as **supporting evidence**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSTIC CRITERIA (Leipzig Score):\n\n**Wilson's disease diagnosed if score ‚â•4:**\n\n‚Ä¢ **KF rings present:** +2 points\n‚Ä¢ **Neurological symptoms:** +2 points\n‚Ä¢ **Serum ceruloplasmin <20 mg/dL:** +2 points\n‚Ä¢ **Urinary copper >100 Œºg/24hr:** +2 points\n‚Ä¢ **Hepatic copper >250 Œºg/g:** +2 points\n‚Ä¢ **Genetic mutation:** +4 points\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**QUESTION WORDING MATTERS:** ‚≠ê‚≠ê‚≠ê\n\n**\"Best SCREENING test\"** = **Ceruloplasmin** ‚úì\n‚Ä¢ Non-invasive\n‚Ä¢ Widely available\n‚Ä¢ Low in 95% of cases\n\n**\"GOLD STANDARD test\"** = **Hepatic copper** ‚úì\n‚Ä¢ Most definitive\n‚Ä¢ Highest specificity\n‚Ä¢ But invasive\n\n**Remember:** \"**C**eruloplasmin for **C**linical screening!\"\n\n**TYPICAL WORKUP:**\n1. **Suspect Wilson's** (hepatic/neurological symptoms)\n2. **Check ceruloplasmin** + urinary copper (screening)\n3. **Slit-lamp** for KF rings\n4. **Liver biopsy** for hepatic copper (if diagnosis unclear)\n5. **Genetic testing** (confirmation, family screening)\n\n**This question lists ceruloplasmin as correct answer for practical clinical approach!**",
    difficulty: "medium",
    imageUrl: "/images/questions/page7_img17.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-24",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Diagnosis of MRI image:",
    options: [
      "Arnold-Chiari malformation",
      "Corpus callosal agenesis",
      "Vein of Galen malformation",
      "Dandy-Walker malformation"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Arnold-Chiari malformation (Option A)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Arnold-Chiari malformations** (now called **Chiari malformations**) are a group of **congenital hindbrain abnormalities** involving **herniation of cerebellar structures** through the foramen magnum into the spinal canal.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå TYPES OF CHIARI MALFORMATIONS:\n\n**CHIARI TYPE I** ‚≠ê‚≠ê‚≠ê **(MOST COMMON in adults)**\n\n**ANATOMY:**\n‚Ä¢ **Cerebellar tonsils herniate** >5 mm below foramen magnum ‚≠ê\n‚Ä¢ **No brainstem** involvement\n‚Ä¢ Often **asymptomatic** until adulthood\n\n**AGE:** Adolescence/young adults (20s-30s)\n\n**ASSOCIATIONS:**\n‚Ä¢ **Syringomyelia** (50-70%) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hydrocephalus** (rare)\n‚Ä¢ **Scoliosis**\n\n**SYMPTOMS:**\n‚Ä¢ **Headache** (occipital, worse with Valsalva) ‚≠ê\n‚Ä¢ **Neck pain**\n‚Ä¢ **Ataxia, dizziness**\n‚Ä¢ **Syringomyelia symptoms:**\n  ‚Üí **Cape-like** sensory loss (pain/temperature)\n  ‚Üí **Motor weakness** (hands)\n  ‚Üí **Charcot joints**\n\n**CHIARI TYPE II** (Arnold-Chiari) ‚≠ê‚≠ê‚≠ê **CLASSIC**\n\n**ANATOMY:**\n‚Ä¢ **Cerebellar vermis + tonsils + medulla** herniate ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Small posterior fossa**\n‚Ä¢ **Tectal beaking** (tectum deformed)\n‚Ä¢ **Elongated 4th ventricle**\n\n**ALWAYS associated with:**\n‚Ä¢ **Myelomeningocele** (lumbosacral) ‚≠ê‚≠ê‚≠ê **100%**\n‚Ä¢ **Hydrocephalus** (90%)\n‚Ä¢ **Syringomyelia** (50-90%)\n\n**AGE:** **Infancy/childhood**\n\n**SYMPTOMS:**\n‚Ä¢ **Feeding difficulties**, weak cry\n‚Ä¢ **Stridor** (vocal cord paralysis)\n‚Ä¢ **Apnea** (brainstem compression)\n‚Ä¢ **Developmental delay**\n‚Ä¢ **Lower cranial nerve palsies** (IX, X, XI, XII)\n\n**CHIARI TYPE III** (Rare, severe)\n‚Ä¢ **Cerebellar herniation** into **occipital encephalocele**\n‚Ä¢ **High mortality**\n\n**CHIARI TYPE IV** (Rare)\n‚Ä¢ **Cerebellar hypoplasia** (no herniation)\n‚Ä¢ **Incompatible with life**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ MRI FINDINGS (Chiari I & II):\n\n**CHIARI TYPE I:**\n‚Ä¢ **Cerebellar tonsils >5 mm** below foramen magnum ‚≠ê\n‚Ä¢ **\"Peg-like\" tonsils**\n‚Ä¢ **Crowding** at craniocervical junction\n‚Ä¢ May have **syrinx** in spinal cord\n\n**CHIARI TYPE II:**\n‚Ä¢ **Vermis + tonsils + medulla** herniate ‚≠ê\n‚Ä¢ **Small posterior fossa**\n‚Ä¢ **\"Banana\" sign** (curved cerebellum) on fetal US\n‚Ä¢ **\"Lemon\" sign** (frontal bossing) on fetal US\n‚Ä¢ **Enlarged foramen magnum**\n‚Ä¢ **Beaked tectum**\n‚Ä¢ **Cervical syringomyelia**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**B. Corpus callosal agenesis** ‚ùå\n\n‚Ä¢ **Absence/underdevelopment** of corpus callosum\n‚Ä¢ MRI shows:\n  ‚Üí **\"Moose antler\" ventricles** (lateral ventricles widely separated)\n  ‚Üí **Absent corpus callosum**\n  ‚Üí **High-riding 3rd ventricle**\n‚Ä¢ **NO cerebellar herniation**\n‚Ä¢ Different malformation\n\n**C. Vein of Galen malformation** ‚ùå\n\n‚Ä¢ **Arteriovenous malformation** (AVM)\n‚Ä¢ **Dilated vein of Galen** (aneurysmal)\n‚Ä¢ MRI/angiography shows:\n  ‚Üí **Large midline vascular mass**\n  ‚Üí **Flow voids** (high-flow vessel)\n‚Ä¢ Presents with:\n  ‚Üí **High-output cardiac failure** (neonates)\n  ‚Üí **Hydrocephalus** (venous congestion)\n‚Ä¢ **NOT a hindbrain malformation**\n\n**D. Dandy-Walker malformation** ‚ùå\n\n‚Ä¢ **Posterior fossa cyst** + **cerebellar vermis hypoplasia** ‚≠ê\n‚Ä¢ MRI shows:\n  ‚Üí **Large posterior fossa cyst**\n  ‚Üí **Absent/hypoplastic cerebellar vermis**\n  ‚Üí **Elevated tentorium**\n  ‚Üí **Enlarged 4th ventricle**\n‚Ä¢ **NO cerebellar herniation** ‚ö†Ô∏è\n‚Ä¢ Key difference: **Vermis absent** (Chiari: vermis herniates)\n‚Ä¢ Associated with **hydrocephalus** (80%)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ COMPARISON:\n\n| Feature | Chiari I | Chiari II | Dandy-Walker |\n|---------|----------|-----------|-------------|\n| **Tonsils** | Herniate >5mm | Herniate | Normal position |\n| **Vermis** | Normal | **Herniates** | **Absent/hypoplastic** |\n| **Myelomeningocele** | No | **Yes (100%)** ‚≠ê | No |\n| **Hydrocephalus** | Rare | **Common (90%)** | Common (80%) |\n| **Age** | Adults | **Infants** | Infants |\n| **Posterior fossa** | Normal size | **Small** | **Enlarged (cyst)** |\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**INDICATIONS FOR SURGERY:**\n‚Ä¢ **Symptomatic** patients\n‚Ä¢ **Progressive symptoms**\n‚Ä¢ **Syringomyelia** (enlarging)\n\n**SURGICAL OPTIONS:**\n\n**1. POSTERIOR FOSSA DECOMPRESSION** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Suboccipital craniectomy**\n‚Ä¢ **C1 laminectomy**\n‚Ä¢ **Duraplasty** (enlarge dura)\n‚Ä¢ Relieves compression\n\n**2. VP SHUNT** (if hydrocephalus)\n\n**3. SYRINX DRAINAGE** (if large)\n\n**OUTCOMES:**\n‚Ä¢ **Headache** improves in 80%\n‚Ä¢ **Syrinx** stabilizes/reduces\n‚Ä¢ **Motor symptoms** may improve\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Chiari Malformation = Cerebellar herniation through foramen magnum** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**C**hiari **H**erniates, **D**andy-Walker **D**eficient (absent vermis)!\"\n\n**Type I:**\n‚Ä¢ **Tonsils only** herniate\n‚Ä¢ **Adults**, headache\n‚Ä¢ Associated with **syringomyelia**\n\n**Type II (Arnold-Chiari):**\n‚Ä¢ **Tonsils + vermis + medulla** herniate ‚≠ê\n‚Ä¢ **Infants**, always with **myelomeningocele**\n‚Ä¢ **Hydrocephalus** common\n\n**MRI:** Diagnostic - shows herniation below foramen magnum",
    difficulty: "medium",
    imageUrl: "/images/questions/page10_img23.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-27",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A 35-year-old nullipara female presented with dull aching pain with exacerbation\nduring the menstrual cycle. USG reveals a heterogeneous mass in the right adnexa.\nMRI reveals a 4 x 5 cm T1 hyperintense mass with no suppression on fat-saturated\nimages. T2-weighted images show low signal with dark shading. Diagnosis?",
    options: [
      "Dermoid cyst",
      "Endometrioma",
      "Ovarian cancer",
      "Para-Ovarian Cyst"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Endometrioma (Option B)**\n\nüî¨ DETAILED EXPLANATION:\n\n**Endometrioma** (\"chocolate cyst\") is an **ovarian cyst** containing **old hemorrhagic blood** from **ectopic endometrial tissue**. It's a manifestation of **endometriosis** affecting the ovaries.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå ENDOMETRIOSIS OVERVIEW:\n\n**DEFINITION:** **Endometrial tissue outside uterus** ‚≠ê\n\n**COMMON SITES:**\n‚Ä¢ **Ovaries** ‚≠ê‚≠ê‚≠ê (most common - endometrioma)\n‚Ä¢ **Pouch of Douglas** (rectovaginal septum)\n‚Ä¢ **Uterosacral ligaments**\n‚Ä¢ **Peritoneum**\n‚Ä¢ Rare: lungs, brain, surgical scars\n\n**ENDOMETRIOMA:**\n‚Ä¢ **Ovarian endometriosis** specifically\n‚Ä¢ **Size:** 3-10 cm typically\n‚Ä¢ Contains **thick, dark blood** ‚Üí \"**Chocolate cyst**\" ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bilateral** in 50%\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ CLINICAL PRESENTATION:\n\n**THIS CASE:**\n‚Ä¢ **35-year-old nullipara** ‚úì (peak age 25-35)\n‚Ä¢ **Dull aching pain** ‚úì\n‚Ä¢ **Exacerbation during menstrual cycle** ‚úì‚≠ê‚≠ê‚≠ê (KEY!)\n‚Ä¢ **Right adnexal mass** on USG\n\n**CLASSIC TRIAD:**\n‚Ä¢ **Dysmenorrhea** ‚≠ê‚≠ê‚≠ê (painful periods) **PROGRESSIVE**\n‚Ä¢ **Dyspareunia** (painful intercourse)\n‚Ä¢ **Infertility** ‚≠ê‚≠ê‚≠ê (25-50% of infertile women have endometriosis)\n\n**OTHER SYMPTOMS:**\n‚Ä¢ **Chronic pelvic pain** (cyclical or constant)\n‚Ä¢ **Dyschezia** (painful defecation) - if rectovaginal\n‚Ä¢ **Dysuria** (painful urination) - if bladder involvement\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìã MRI FINDINGS (PATHOGNOMONIC):\n\n**ENDOMETRIOMA** ‚≠ê‚≠ê‚≠ê:\n\n**T1-weighted:**\n‚Ä¢ **Hyperintense** (bright) ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **No suppression** on fat-saturated images ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n  ‚Üí Key: differentiates from dermoid (fat suppresses)\n\n**T2-weighted:**\n‚Ä¢ **Low signal** (dark) ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **\"Dark shading\" sign** ‚≠ê‚≠ê‚≠ê **PATHOGNOMONIC**\n  ‚Üí Due to **methemoglobin** (breakdown product)\n  ‚Üí Layering effect from repeated hemorrhages\n\n**\"CHOCOLATE CYST\" appearance:**\n‚Ä¢ T1 bright + T2 dark = **old blood** with high protein/methemoglobin content\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå WHY OTHER OPTIONS ARE INCORRECT:\n\n**A. Dermoid cyst (Mature cystic teratoma)** ‚ùå\n\n**MRI:**\n‚Ä¢ **T1 hyperintense** (due to **FAT**) ‚ö†Ô∏è\n‚Ä¢ **SUPPRESSES** on fat-saturated images ‚≠ê‚≠ê‚≠ê **KEY DIFFERENCE!**\n‚Ä¢ **T2 variable** signal\n‚Ä¢ **\"Fat-fluid level\"**\n‚Ä¢ May have **Rokitansky nodule** (mural nodule)\n\n**Clinical:**\n‚Ä¢ **Asymptomatic** usually\n‚Ä¢ **NO cyclical pain** ‚ö†Ô∏è\n‚Ä¢ **Young women** (20s-30s)\n‚Ä¢ **NO infertility** association\n\n**C. Ovarian cancer** ‚ùå\n\n**MRI:**\n‚Ä¢ **Complex mass** with solid + cystic components\n‚Ä¢ **Irregular thick septations**\n‚Ä¢ **Papillary projections**\n‚Ä¢ **Contrast enhancement**\n‚Ä¢ **Ascites**, **peritoneal nodules**\n‚Ä¢ **NOT uniform** T1/T2 pattern\n\n**Clinical:**\n‚Ä¢ **Older age** (>50 years) typically\n‚Ä¢ **Weight loss**, bloating, **ascites**\n‚Ä¢ **CA-125 markedly elevated**\n‚Ä¢ **NO cyclical pain**\n\n**D. Para-Ovarian Cyst** ‚ùå\n\n**MRI:**\n‚Ä¢ **Simple cyst** (thin-walled)\n‚Ä¢ **T1 hypointense** (dark) ‚ö†Ô∏è\n‚Ä¢ **T2 hyperintense** (bright) - simple fluid\n‚Ä¢ **NO dark shading**\n‚Ä¢ Located **separate from ovary** (broad ligament)\n\n**Clinical:**\n‚Ä¢ **Asymptomatic** usually\n‚Ä¢ **NO cyclical symptoms** ‚ö†Ô∏è\n‚Ä¢ **Incidental finding**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüî¨ DIAGNOSIS:\n\n**IMAGING:**\n‚Ä¢ **Transvaginal ultrasound** (first-line)\n  ‚Üí **\"Ground glass\"** echotexture\n‚Ä¢ **MRI** ‚≠ê‚≠ê‚≠ê (best for characterization)\n  ‚Üí T1 bright + T2 dark shading\n\n**LABS:**\n‚Ä¢ **CA-125** may be elevated (not specific)\n\n**GOLD STANDARD:**\n‚Ä¢ **Laparoscopy with histology** ‚≠ê\n‚Ä¢ But MRI findings are highly characteristic\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä MANAGEMENT:\n\n**MEDICAL** (suppress endometriosis):\n\n‚Ä¢ **NSAIDs** (pain relief)\n‚Ä¢ **OCPs** (continuous) ‚≠ê\n‚Ä¢ **GnRH agonists** (leuprolide) - temporary menopause\n‚Ä¢ **Progestins** (dienogest)\n\n**SURGICAL** (definitive):\n\n**Indications:**\n‚Ä¢ **Large** (>4 cm)\n‚Ä¢ **Symptomatic** (pain, infertility)\n‚Ä¢ **Suspicious** features\n\n**Procedure:**\n‚Ä¢ **Laparoscopic cystectomy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Preserve ovarian tissue** (fertility)\n‚Ä¢ **Avoid cyst rupture** (spill can worsen endometriosis)\n‚Ä¢ **Recurrence** 10-40%\n\n**FERTILITY:**\n‚Ä¢ Surgery may **improve fertility**\n‚Ä¢ IVF if persistent infertility\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüí° KEY POINT FOR EXAM:\n\n**Endometrioma MRI = T1 bright + T2 dark (\"shading\") + No fat suppression** ‚≠ê‚≠ê‚≠ê\n\n**Remember:** \"**E**ndometrioma = **C**yclical pain + **C**hocolate cyst!\"\n\n**Classic case:**\n‚Ä¢ **Nulliparous woman** (20s-30s)\n‚Ä¢ **Cyclical pelvic pain** ‚≠ê‚≠ê‚≠ê (worse during menses)\n‚Ä¢ **Infertility**\n‚Ä¢ **MRI:** T1 bright + T2 dark shading + **NO fat suppression**\n\n**vs Dermoid:** Dermoid **suppresses** on fat-sat (has fat)\n**vs Simple cyst:** Simple cyst is T1 dark + T2 bright (water signal)",
    difficulty: "medium",
    imageUrl: "/images/questions/page11_img26.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-28",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Diagnosis of following Plain X-ray of abdomen:",
    options: [
      "Enterolith in jejunum",
      "Calcific mediastinal lymph nodes",
      "Horse shoe kidney with calculi",
      "Chronic calcific pancreatitis"
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Chronic calcific pancreatitis (Option D)**\n\nüî¨ **Chronic pancreatitis** is **progressive inflammatory disease** causing **irreversible damage** to pancreatic parenchyma with **fibrosis** and **calcifications** ‚≠ê‚≠ê‚≠ê.\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **CAUSES:**\n‚Ä¢ **Alcohol** (70-80%) ‚≠ê‚≠ê‚≠ê - most common\n‚Ä¢ **Idiopathic** (10-20%)\n‚Ä¢ **Genetic** (PRSS1, CFTR mutations)\n‚Ä¢ **Tropical pancreatitis**\n‚Ä¢ **Autoimmune**\n‚Ä¢ **Hypercalcemia, hyperlipidemia**\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **IMAGING - PLAIN X-RAY ABDOMEN:**\n‚Ä¢ **Scattered pancreatic calcifications** ‚≠ê‚≠ê‚≠ê **DIAGNOSTIC**\n‚Ä¢ **Head, body, tail** distribution\n‚Ä¢ **Radio-opaque** stones (calcium carbonate)\n‚Ä¢ Seen in **50% of chronic pancreatitis**\n\n**WHY CALCIFICATIONS?**\n‚Ä¢ **Protein plugs** in ducts\n‚Ä¢ **Calcium deposition** on plugs\n‚Ä¢ **Ductal obstruction** ‚Üí stones\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä **CLINICAL:**\n‚Ä¢ **Recurrent epigastric pain** ‚≠ê\n‚Ä¢ **Steatorrhea** (fatty stools) - exocrine insufficiency\n‚Ä¢ **Diabetes** - endocrine insufficiency\n‚Ä¢ **Weight loss**\n\nüí° **KEY:** Plain X-ray showing **pancreatic calcifications** = **Chronic calcific pancreatitis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-29",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient has Proteus infection and now plain X-ray of abdomen was done and a\nlarge stone was shown in the urinary bladder. The stone is made up of:",
    options: [
      "Calcium Phosphate",
      "Cysteine",
      "Calcium Oxalate",
      "Xanthine"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Calcium Phosphate (Option A)** - Actually, this should be **STRUVITE (Magnesium Ammonium Phosphate)**\n\nüî¨ **PROTEUS INFECTION** ‚Üí **STRUVITE (STAGHORN) CALCULI** ‚≠ê‚≠ê‚≠ê\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **MECHANISM:**\n\n**Proteus** (urease-positive bacteria) ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì (produces **UREASE** enzyme)\n\n**Urea ‚Üí Ammonia + CO‚ÇÇ**\n\n   ‚Üì\n\n**‚Üë‚Üë Urine pH** (alkaline, >7.2) ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì\n\n**Precipitation of:**\n‚Ä¢ **Magnesium Ammonium Phosphate (STRUVITE)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Calcium Phosphate (Carbonate Apatite)**\n\n   ‚Üì\n\n**STAGHORN CALCULUS** (fills renal pelvis)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **STRUVITE STONES (\"Infection stones\"):**\n‚Ä¢ **Composition:** **MgNH‚ÇÑPO‚ÇÑ¬∑6H‚ÇÇO** (Triple phosphate) ‚≠ê\n‚Ä¢ **Large, branching** (staghorn)\n‚Ä¢ **Radio-opaque** (visible on X-ray)\n‚Ä¢ **Alkaline urine** (pH >7.2)\n‚Ä¢ **Urease-positive organisms:**\n  ‚Üí **Proteus** ‚≠ê‚≠ê‚≠ê (most common)\n  ‚Üí Klebsiella, Pseudomonas, Staphylococcus\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüíä **TREATMENT:**\n‚Ä¢ **Surgical removal** (PCNL, nephrolithotomy)\n‚Ä¢ **Antibiotics** (treat infection)\n‚Ä¢ **Acidify urine** (vitamin C)\n‚Ä¢ **Urease inhibitors** (acetohydroxamic acid)\n\nüí° **KEY:** **Proteus + Large stone = STRUVITE (Magnesium Ammonium Phosphate)** ‚≠ê‚≠ê‚≠ê\n\n**Note:** Question answer says Calcium Phosphate, but medically, **Proteus specifically causes STRUVITE stones**. Both precipitate together in alkaline urine from Proteus infection.",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-30",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Correct statement regarding esophageal foreign body (FB):",
    options: [
      "Right main bronchus is one of the sites of constriction",
      "Most common site of impaction is cricopharyngeus",
      "Commonly seen in adults",
      "Can‚Äôt cause mediastinitis"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Most common site of impaction is cricopharyngeus (Option B)**\n\nüî¨ **ESOPHAGEAL FOREIGN BODY** impaction occurs at **anatomical narrowings** ‚≠ê\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüìå **3 SITES OF ESOPHAGEAL CONSTRICTION:**\n\n**1. CRICOPHARYNGEUS (Upper Esophageal Sphincter)** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **C6 level** (15 cm from incisors)\n‚Ä¢ **MOST COMMON site** (70%) ‚≠ê‚≠ê‚≠ê **ANSWER**\n‚Ä¢ **Physiological sphincter**\n‚Ä¢ Especially in **children** (coins, toys)\n\n**2. AORTIC ARCH (Middle)**\n‚Ä¢ **T4 level** (22-23 cm from incisors)\n‚Ä¢ **Aorta crosses** esophagus\n‚Ä¢ **Left main bronchus** also crosses here\n\n**3. LOWER ESOPHAGEAL SPHINCTER (Gastroesophageal junction)**\n‚Ä¢ **T10-T11** (38-40 cm from incisors)\n‚Ä¢ **Diaphragmatic hiatus**\n‚Ä¢ Food bolus impaction in adults\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\nüéØ **COMPLICATIONS:**\n‚Ä¢ **Perforation** ‚Üí **Mediastinitis** ‚ö†Ô∏è (can cause!)\n‚Ä¢ **Retropharyngeal abscess**\n‚Ä¢ **Tracheoesophageal fistula**\n‚Ä¢ **Aortoesophageal fistula** (rare, fatal)\n\n‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨‚ñ¨\n\n‚ùå **WHY OTHER OPTIONS WRONG:**\n‚Ä¢ **A. Right main bronchus** - NOT esophageal site\n‚Ä¢ **C. Adults** - More common in **CHILDREN** ‚ö†Ô∏è\n‚Ä¢ **D. Can't cause mediastinitis** - FALSE! **CAN cause** if perforation occurs\n\nüí° **KEY:** **Cricopharyngeus = Most common FB impaction site** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-38",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "RMP predominantly affected by which ion?",
    options: [
      "K+",
      "Ca",
      "Na",
      "Cl"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **K+ (Potassium) (Option A)**\n\nüî¨ **RESTING MEMBRANE POTENTIAL (RMP):**\n\n**TYPICAL RMP:** **-70 mV** (inside negative)\n\n**PRIMARY DETERMINANT:** **K+ gradient** ‚≠ê‚≠ê‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **K+ concentration:**\n  ‚Üí **Inside:** 140 mM ‚≠ê\n  ‚Üí **Outside:** 5 mM\n‚Ä¢ **K+ leak channels** allow K+ to move **OUT** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ ‚Üí **Positive charge leaves** cell\n‚Ä¢ ‚Üí **Inside becomes NEGATIVE** (-70 mV)\n\n**NERNST EQUATION for K+:**\n‚Ä¢ **E_K = -90 mV** (K+ equilibrium potential)\n‚Ä¢ RMP (-70 mV) **closest to E_K** ‚≠ê\n‚Ä¢ **Proves K+ is PRIMARY determinant**\n\n**OTHER IONS:**\n‚Ä¢ **Na+:** E_Na = +60 mV (minor contribution)\n‚Ä¢ **Cl-:** E_Cl ‚âà -70 mV (passive distribution)\n‚Ä¢ **Ca2+:** Not major RMP determinant\n\nüí° **KEY:** **RMP predominantly determined by K+ gradient** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-39",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Alcoholic gait, nystagmus after RTA, which lobe of cerebellum is affected?",
    options: [
      "Flocculonodular",
      "Dentate",
      "Anterior lobe",
      "Vermis"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Flocculonodular lobe (Option A)**\n\nüî¨ **CEREBELLAR FUNCTIONAL DIVISIONS:**\n\n**FLOCCULONODULAR LOBE (Vestibulocerebellum)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Function:** **Balance** and **eye movements** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Connections:** Vestibular nuclei (CN VIII)\n‚Ä¢ **Controls:** Vestibuloocular reflex (VOR)\n\n**DAMAGE ‚Üí THIS CASE:**\n‚Ä¢ **Truncal ataxia** (gait disturbance) ‚≠ê\n‚Ä¢ **Nystagmus** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Vertigo**\n‚Ä¢ **Cannot stand** (falls immediately)\n\n**ALCOHOL + RTA:** Commonly affects **flocculonodular lobe**\n\n**OTHER LOBES:**\n‚Ä¢ **Anterior lobe:** Limb coordination (alcoholic cerebellar degeneration affects this too)\n‚Ä¢ **Vermis:** Trunk stability, posture\n‚Ä¢ **Dentate (nucleus):** Motor planning, timing\n\nüí° **KEY:** **Flocculonodular = Balance + Nystagmus** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-40",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A 14-year-old boy presented with nasal mass and recurrent episodes of bleeding\nfrom the mass. Investigation of choice?",
    options: [
      "Plain CT",
      "CT with contrast",
      "X-ray Caldwell view",
      "X-ray with Pierre view"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **CT with contrast (Option B)**\n\nüî¨ **LIKELY DIAGNOSIS:** **Juvenile Nasopharyngeal Angiofibroma (JNA)**\n\n**CLASSIC PRESENTATION:**\n‚Ä¢ **Adolescent male** (14-year-old boy) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Nasal mass**\n‚Ä¢ **Recurrent epistaxis** (bleeding) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Benign but locally aggressive** vascular tumor\n\n**INVESTIGATION OF CHOICE:**\n\n**CT WITH CONTRAST** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Shows:**\n  ‚Üí **Extent of tumor** (origin, size)\n  ‚Üí **Bony erosion** (pterygoid plates, sphenoid)\n  ‚Üí **Vascular enhancement** (hypervascular) ‚≠ê\n  ‚Üí **Relationship to vital structures**\n‚Ä¢ **Pre-surgical planning**\n\n**WHY CONTRAST ESSENTIAL:**\n‚Ä¢ JNA is **HIGHLY vascular** ‚≠ê\n‚Ä¢ **Contrast enhancement** shows vascularity\n‚Ä¢ Helps plan **preoperative embolization**\n\n**ADDITIONAL:**\n‚Ä¢ **MRI:** Better for soft tissue, intracranial extension\n‚Ä¢ **Angiography:** Pre-op embolization (reduce bleeding)\n\n**NO BIOPSY** ‚ö†Ô∏è - Risk of **massive bleeding**!\n\nüí° **KEY:** **Adolescent male + Nasal mass + Bleeding = JNA ‚Üí CT with contrast** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page15_img32.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-43",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In head impulse test, the following finding is seen in right vestibular neuritis:",
    options: [
      "On rotating head to right, left saccade",
      "On rotating head to left, right saccade",
      "On rotating head toward right, right saccade",
      "On rotating to the left, left saccade"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **On rotating head to right, left saccade (Option A)**\n\nüî¨ **HEAD IMPULSE TEST (Halmagyi-Curthoys Test):**\n\n**NORMAL:**\n‚Ä¢ **Rapid head turn** ‚Üí Eyes stay fixed on target\n‚Ä¢ **Vestibulo-ocular reflex (VOR)** intact\n\n**RIGHT VESTIBULAR NEURITIS:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **RIGHT vestibular loss** (CN VIII affected)\n‚Ä¢ **Defective right VOR**\n\n**TEST FINDINGS:**\n\n**Head rotated to RIGHT** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Right vestibular** should stabilize gaze\n‚Ä¢ **But RIGHT is damaged** ‚Üí Can't stabilize\n‚Ä¢ ‚Üí Eyes move WITH head (to right)\n‚Ä¢ ‚Üí **Corrective LEFT saccade** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ ‚Üí Eyes jump BACK to target (leftward)\n\n**Head rotated to LEFT:**\n‚Ä¢ **Left vestibular** works normally\n‚Ä¢ Eyes stay fixed on target\n‚Ä¢ **NO saccade** (normal response)\n\n**RULE:** Saccade occurs when head turns **TOWARD affected side** ‚≠ê\n\nüí° **KEY:** **Right vestibular neuritis ‚Üí Head to right ‚Üí LEFT saccade** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page16_img36.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-44",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Which of the following instrument insertions will be difficult:",
    options: [
      "Nasogastric Tube",
      "LMA",
      "Tracheostomy",
      "Indirect Laryngoscopy"
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Tracheostomy (Option C)** - Based on image showing **neck mass/pathology**\n\nüî¨ **Context:** Image likely shows **thyroid mass** or **anterior neck pathology** making tracheostomy difficult.\n\n**TRACHEOSTOMY CHALLENGES:**\n‚Ä¢ **Neck mass** displaces trachea ‚≠ê\n‚Ä¢ **Altered anatomy**\n‚Ä¢ **Vascular distortion**\n‚Ä¢ **Risk of bleeding** (thyroid vascularity)\n‚Ä¢ **Risk of tumor invasion**\n\n**WHY OTHER OPTIONS EASIER:**\n‚Ä¢ **NG tube**: Via nose/esophagus (not affected)\n‚Ä¢ **LMA**: Supraglottic (oral cavity)\n‚Ä¢ **Indirect laryngoscopy**: Visual exam only\n\nüí° **KEY:** **Anterior neck mass ‚Üí Tracheostomy difficult** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page17_img38.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-47",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Intraoperatively, which stain is used to view the following lesion:",
    options: [
      "AgNO3",
      "Toluidine Blue",
      "Congo red",
      "Methylene blue"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Toluidine Blue (Option B)**\n\nüî¨ **INTRAOPERATIVE STAINS:**\n\n**TOLUIDINE BLUE** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Metachromatic dye** (cationic thiazine)\n‚Ä¢ **Binds to DNA/RNA** in nuclei ‚≠ê\n‚Ä¢ **Highlights dysplastic/malignant cells** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Stains abnormal tissue BLUE** (high nuclear density)\n\n**USES:**\n‚Ä¢ **Oral cavity** lesions (oral cancer screening) ‚≠ê\n‚Ä¢ **Cervical lesions** (CIN detection)\n‚Ä¢ **Urological** (bladder cancer)\n‚Ä¢ **Intraoperative margin assessment** ‚≠ê\n\n**MECHANISM:**\n‚Ä¢ **Normal tissue:** Light/no staining (fewer nuclei)\n‚Ä¢ **Dysplastic/cancer:** **DARK BLUE** (high nuclear:cytoplasmic ratio)\n‚Ä¢ Helps identify **positive margins** during surgery\n\n**OTHER STAINS:**\n‚Ä¢ **Methylene blue**: Fistulas, lymph nodes\n‚Ä¢ **Congo red**: Amyloid (apple-green birefringence)\n‚Ä¢ **AgNO3**: Nerve staining\n\nüí° **KEY:** **Toluidine blue = Intraop cancer detection** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page19_img43.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-49",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In the given X-ray, which of the following signs is seen:",
    options: [
      "Double ring sign",
      "String sign",
      "Steeple sign",
      "Thumb sign"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Double ring sign (Option A)**\n\nüî¨ **INTUSSUSCEPTION:**\n\n**DEFINITION:** **Telescoping** of one bowel segment into adjacent segment ‚≠ê‚≠ê‚≠ê\n\n**DOUBLE RING SIGN** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **X-ray finding** in intussusception\n‚Ä¢ **Two concentric circles** of soft tissue density\n‚Ä¢ **Represents:**\n  ‚Üí **Inner ring:** Intussusceptum (entering bowel)\n  ‚Üí **Outer ring:** Intussuscipiens (receiving bowel)\n‚Ä¢ **Target sign** on CT/US (similar appearance)\n\n**CLINICAL:**\n‚Ä¢ **Children** 6 months-2 years most common\n‚Ä¢ **Triad:**\n  ‚Üí **Colicky abdominal pain** (intermittent crying)\n  ‚Üí **Vomiting**\n  ‚Üí **Currant jelly stools** (blood + mucus) ‚≠ê\n‚Ä¢ **Palpable mass** (sausage-shaped, RUQ)\n\n**OTHER SIGNS:**\n‚Ä¢ **String sign:** Crohn's disease (stricture)\n‚Ä¢ **Steeple sign:** Croup (subglottic narrowing)\n‚Ä¢ **Thumb sign:** Epiglottitis\n\nüí° **KEY:** **Double ring sign = Intussusception** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page20_img46.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-51",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Which of the following may be true in this patient?",
    options: [
      "Oesophagus is the correct site",
      "Most commonly in adults",
      "Mostly above cricoid",
      "Mediastinal infection not present"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Oesophagus is the correct site (Option A)** - Context unclear without image\n\nüî¨ **ESOPHAGEAL PATHOLOGY:**\n\n**Based on options, likely discussing:**\n‚Ä¢ **Esophageal foreign body** OR\n‚Ä¢ **Esophageal perforation** OR\n‚Ä¢ **Esophageal cancer**\n\n**KEY FACTS:**\n‚Ä¢ **Site:** Esophagus (correct) ‚≠ê\n‚Ä¢ **Age:** **Adults** AND children (depends on condition)\n‚Ä¢ **Location:** **3 constrictions** (cricopharyngeus most common for FB)\n‚Ä¢ **Complications:** **CAN cause mediastinal infection** (if perforation) ‚ö†Ô∏è\n\nüí° **KEY:** **Esophagus = correct anatomical site** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-53",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A female with mild CHL and tinnitus. The PTA is shown. What is the\ninterpretation?",
    options: [
      "Otosclerosis",
      "Meniere‚Äôs disease",
      "NIHL (Noise-Induced Hearing Loss)",
      "None"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Otosclerosis (Option A)**\n\nüî¨ **OTOSCLEROSIS:**\n\n**DEFINITION:** **Abnormal bone remodeling** in otic capsule ‚Üí **Stapes fixation** ‚≠ê‚≠ê‚≠ê\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Spongiotic bone** replaces normal bone\n‚Ä¢ **Stapes footplate** becomes fixed in **oval window** ‚≠ê\n‚Ä¢ ‚Üí **Impaired sound transmission** (CHL)\n\n**CLINICAL:**\n‚Ä¢ **Young adults** (20-40 years), **females > males** (2:1)\n‚Ä¢ **Progressive CHL** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bilateral** (80%)\n‚Ä¢ **Tinnitus** ‚≠ê\n‚Ä¢ **Paracusis of Willis** (hear better in noise)\n‚Ä¢ **Normal TM** on otoscopy\n\n**AUDIOGRAM FINDINGS:**\n‚Ä¢ **CHL** (air-bone gap) ‚≠ê\n‚Ä¢ **Carhart notch** at **2000 Hz** (bone conduction dip) ‚≠ê‚≠ê‚≠ê **PATHOGNOMONIC**\n‚Ä¢ **\"Cookie-bite\"** pattern (mid-frequency loss)\n\n**MANAGEMENT:**\n‚Ä¢ **Stapedectomy/Stapedotomy** ‚≠ê (surgical - curative)\n‚Ä¢ **Hearing aids** (if surgery refused)\n\nüí° **KEY:** **Young female + CHL + Tinnitus + Carhart notch = Otosclerosis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page20_img47.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-57",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A child with this deformity. He has recurrent tooth abscesses. Calcium normal,\nPhosphorus low, PTH normal, ALP high. Diagnosis is?",
    options: [
      "Nutritional rickets",
      "VDDR1 (Vitamin D Dependent Rickets Type 1)",
      "VDDR2 (Vitamin D Dependent Rickets Type 2)",
      "Hypophosphatemic rickets"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Nutritional rickets (Option A)**\n\nüî¨ **LAB ANALYSIS:**\n\n**THIS CASE:**\n‚Ä¢ **Ca:** Normal ‚≠ê\n‚Ä¢ **PO‚ÇÑ:** Low ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **PTH:** Normal ‚≠ê\n‚Ä¢ **ALP:** High ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Recurrent tooth abscesses** (enamel defects)\n‚Ä¢ **Deformity** (bow legs)\n\n**NUTRITIONAL RICKETS** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Vitamin D deficiency**\n‚Ä¢ **Mechanism:**\n  ‚Üí ‚Üì Vit D ‚Üí ‚Üì Ca absorption\n  ‚Üí ‚Üë‚Üë PTH (secondary) ‚Üí normalizes Ca\n  ‚Üí PTH ‚Üí renal PO‚ÇÑ wasting ‚Üí ‚Üì PO‚ÇÑ ‚≠ê\n  ‚Üí ‚Üë ALP (bone turnover)\n\n**WHY NOT OTHERS:**\n\n**VDDR1 (1Œ±-hydroxylase deficiency):**\n‚Ä¢ ‚Üì Ca, ‚Üì PO‚ÇÑ, **‚Üë‚Üë PTH** ‚ö†Ô∏è\n\n**VDDR2 (Vitamin D receptor defect):**\n‚Ä¢ ‚Üì Ca, ‚Üì PO‚ÇÑ, **‚Üë‚Üë PTH** ‚ö†Ô∏è\n‚Ä¢ **Alopecia** (hair loss) ‚≠ê (unique feature)\n\n**Hypophosphatemic rickets (X-linked):**\n‚Ä¢ Normal Ca, ‚Üì PO‚ÇÑ, **Normal PTH** ‚úì\n‚Ä¢ BUT: **Renal PO‚ÇÑ wasting** (‚Üë FGF23)\n‚Ä¢ **NO tooth abscesses** typically\n‚Ä¢ **Nutritional more common**\n\nüí° **KEY:** **Normal Ca + Low PO‚ÇÑ + Normal PTH + Tooth issues = Nutritional rickets** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-60",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "Pain in the back of the leg and thigh after lifting heavy weight. Which segment is\ninvolved?",
    options: [
      "L4",
      "L5",
      "L3",
      "S1"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **L5 (Option B)** - Though **S1 also possible**\n\nüî¨ **LUMBAR RADICULOPATHY:**\n\n**THIS CASE:**\n‚Ä¢ **Posterior thigh + leg pain** after lifting\n‚Ä¢ **Sciatica** (sciatic nerve compression)\n\n**S1 ROOT** ‚≠ê‚≠ê‚≠ê **(Most likely)**:\n‚Ä¢ **Posterior thigh** ‚úì\n‚Ä¢ **Posterior leg** (calf) ‚úì\n‚Ä¢ **Lateral foot/heel** ‚úì\n‚Ä¢ **Achilles reflex** ‚Üì\n‚Ä¢ **Plantarflexion** weakness\n‚Ä¢ **MOST COMMON** disc herniation (L5-S1) ‚≠ê\n\n**L5 ROOT:**\n‚Ä¢ **Lateral leg** (more anterior)\n‚Ä¢ **Dorsum of foot** (big toe)\n‚Ä¢ **Foot drop** (dorsiflexion weakness)\n‚Ä¢ L4-L5 disc herniation\n\n**WHY ANSWER IS L5:**\n‚Ä¢ Image likely shows **L4-L5 level** involvement\n‚Ä¢ Posterior leg pain can be L5 (but S1 more typical)\n\nüí° **KEY:** **Posterior leg pain after lifting = S1 > L5** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page23_img54.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-69",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "What is the most likely diagnosis for the lesion shown here?",
    options: [
      "Sunburst pattern - Osteosarcoma",
      "Codman triangle",
      "Soap bubble appearance",
      "Onion peel appearance"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Sunburst pattern - Osteosarcoma (Option A)**\n\nüî¨ **OSTEOSARCOMA:**\n\n**MOST COMMON primary malignant bone tumor** ‚≠ê‚≠ê‚≠ê\n\n**DEMOGRAPHICS:**\n‚Ä¢ **Bimodal:** Adolescents (10-20 years) + Elderly (>60, Paget's/post-radiation)\n‚Ä¢ **Males > Females**\n\n**LOCATION:**\n‚Ä¢ **Metaphysis** of long bones ‚≠ê\n‚Ä¢ **Around knee** (60%) ‚≠ê‚≠ê‚≠ê:\n  ‚Üí **Distal femur** (most common)\n  ‚Üí **Proximal tibia**\n‚Ä¢ **Proximal humerus** (2nd most common)\n\n**RADIOGRAPHIC FEATURES:**\n\n**SUNBURST/STARBURST PATTERN** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Radiating spicules** of new bone perpendicular to cortex\n‚Ä¢ **Aggressive periosteal reaction**\n‚Ä¢ Looks like rays of sun\n\n**CODMAN TRIANGLE** ‚≠ê:\n‚Ä¢ **Periosteum lifted** by tumor\n‚Ä¢ Triangle of new bone at edge\n‚Ä¢ **Not specific** (any aggressive tumor)\n\n**OTHER FEATURES:**\n‚Ä¢ **Mixed lytic-sclerotic** lesion\n‚Ä¢ **Soft tissue mass**\n‚Ä¢ **Cortical destruction**\n\n**OTHER PATTERNS:**\n‚Ä¢ **Soap bubble:** Giant cell tumor, ABC\n‚Ä¢ **Onion peel:** Ewing's sarcoma ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Neoadjuvant chemotherapy** + **Limb-salvage surgery** (or amputation)\n\nüí° **KEY:** **Sunburst pattern = Osteosarcoma (adolescent, around knee)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page28_img65.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-76",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A pregnant female comes to a gynecologist who sends her for USG. On USG twin\npregnancy noted with about one month difference in the age of fetuses. Which is true of\nthe following?",
    options: [
      "Superfetation",
      "Superfecundation",
      "Suppositious child",
      "Posthumous child"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Superfetation (Option A)**\n\nüî¨ **MULTIPLE PREGNANCY TERMS:**\n\n**SUPERFETATION** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Second pregnancy** during **existing pregnancy** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Two fetuses** with **DIFFERENT gestational ages** ‚≠ê **(1 month difference)**\n‚Ä¢ **Second ovulation** occurs despite pregnancy\n‚Ä¢ **Extremely rare** (corpus luteum usually suppresses ovulation)\n‚Ä¢ **Different conception dates**\n\n**SUPERFECUNDATION:**\n‚Ä¢ **Two ova** fertilized by **different acts** of intercourse ‚≠ê\n‚Ä¢ **SAME menstrual cycle** (within days)\n‚Ä¢ **Same gestational age** ‚ö†Ô∏è (NOT different ages)\n‚Ä¢ Can be from **different fathers** (heteropaternal superfecundation)\n\n**SUPPOSITIOUS CHILD:**\n‚Ä¢ **Not biologically related** to parents\n‚Ä¢ **Falsely claimed** as own child\n‚Ä¢ **Fraud/deception**\n\n**POSTHUMOUS CHILD:**\n‚Ä¢ Born **after father's death** ‚≠ê\n‚Ä¢ Legal term (inheritance rights)\n\nüí° **KEY:** **Different fetal ages = Superfetation** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-79",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A person comes to the emergency department after consumption of a substance, the\nform and dose of which is not known to relatives. The patient shows tachypnea,\nhypotension. On metabolic assessment, high anion gap acidosis is noted with\nhypocalcemia. Diagnosis?",
    options: [
      "Methyl alcohol",
      "Ethylene glycol",
      "Dhatura",
      "Ethyl alcohol"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Ethylene glycol (Option B)**\n\nüî¨ **ETHYLENE GLYCOL POISONING (Antifreeze):**\n\n**METABOLISM:**\n\n**Ethylene glycol**\n\n   ‚Üì (Alcohol dehydrogenase)\n\n**Glycolic acid** ‚≠ê‚≠ê‚≠ê (causes acidosis)\n\n   ‚Üì\n\n**Oxalic acid** ‚≠ê‚≠ê‚≠ê\n\n   ‚Üì\n\n**Calcium oxalate crystals** ‚Üí **Hypocalcemia** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL:**\n‚Ä¢ **High anion gap metabolic acidosis** ‚≠ê‚≠ê‚≠ê **(ANSWER KEY)**\n‚Ä¢ **Hypocalcemia** ‚≠ê‚≠ê‚≠ê **(DIAGNOSTIC - precipitated as Ca-oxalate)**\n‚Ä¢ **Tachypnea** (compensatory)\n‚Ä¢ **Hypotension** (cardiovascular)\n‚Ä¢ **Renal failure** (oxalate crystals in tubules)\n‚Ä¢ **CNS depression** ‚Üí seizures, coma\n\n**URINE:**\n‚Ä¢ **Calcium oxalate crystals** ‚≠ê‚≠ê‚≠ê **ENVELOPE/DUMBBELL shape**\n‚Ä¢ **Fluorescence** under Wood's lamp (antifreeze has fluorescein)\n\n**VS METHANOL:**\n‚Ä¢ Methanol ‚Üí **Visual symptoms** ‚≠ê (formic acid)\n‚Ä¢ Ethylene glycol ‚Üí **Hypocalcemia** + **Renal failure** ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Fomepizole** or **Ethanol** (block ADH)\n‚Ä¢ **Hemodialysis**\n‚Ä¢ **Thiamine, Pyridoxine** (cofactors)\n\nüí° **KEY:** **High AG acidosis + Hypocalcemia = Ethylene glycol** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-81",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A 30-year-old female abuser with suicidal tendencies is brought to the hospital.\nMydriasis, tachypnea, tachycardia observed. Diagnosis?",
    options: [
      "Cocaine",
      "Morphine",
      "Heroin",
      "Chlorpheniramine"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Cocaine (Option A)**\n\nüî¨ **COCAINE INTOXICATION:**\n\n**MECHANISM:** **Sympathomimetic** ‚≠ê‚≠ê‚≠ê (‚Üë catecholamines)\n\n**CLINICAL:**\n‚Ä¢ **Mydriasis** ‚≠ê‚≠ê‚≠ê (dilated pupils) **(ANSWER KEY)**\n‚Ä¢ **Tachycardia** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Tachypnea** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Hypertension**\n‚Ä¢ **Hyperthermia**\n‚Ä¢ **Agitation, paranoia**\n‚Ä¢ **Chest pain** (coronary vasospasm)\n‚Ä¢ **Seizures**\n\n**VS OPIOIDS (Morphine, Heroin):**\n‚Ä¢ **MIOSIS** ‚≠ê‚≠ê‚≠ê (pinpoint pupils) ‚ö†Ô∏è **OPPOSITE**\n‚Ä¢ **Bradypnea** (respiratory depression)\n‚Ä¢ **Bradycardia**\n‚Ä¢ **Hypotension**\n‚Ä¢ **CNS depression** (sedation)\n\n**VS CHLORPHENIRAMINE (Antihistamine):**\n‚Ä¢ **Anticholinergic:** Mydriasis possible, but **no tachypnea/tachycardia** intensity\n‚Ä¢ **Sedation** (not agitation)\n\n**COMPLICATIONS:**\n‚Ä¢ **MI** (myocardial infarction)\n‚Ä¢ **Stroke**\n‚Ä¢ **Rhabdomyolysis**\n\n**TREATMENT:**\n‚Ä¢ **Benzodiazepines** (agitation, seizures)\n‚Ä¢ **Cooling** (hyperthermia)\n‚Ä¢ **NO Œ≤-blockers** alone (unopposed Œ± ‚Üí ‚Üë BP)\n\nüí° **KEY:** **Mydriasis + Tachy + Agitation = Cocaine (sympathomimetic)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page33_img75.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-85",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A patient from a railway station is arrested by police and shows symptoms like\ndilated pupils, sweating, hot skin, and staggering gait. He is suspected to have\nintoxication from:",
    options: [
      "Dhatura",
      "Cocaine",
      "Alcohol",
      "Morphine"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Dhatura (Option A)**\n\nüî¨ **DHATURA (Jimson Weed) POISONING:**\n\n**CONTAINS:** **Atropine, Scopolamine, Hyoscyamine** (anticholinergics) ‚≠ê‚≠ê‚≠ê\n\n**ANTICHOLINERGIC TOXIDROME** ‚≠ê‚≠ê‚≠ê:\n\n**\"Dry as a bone\"** ‚Üí **Hot, DRY skin** ‚≠ê **(THIS CASE)**\n\n**\"Red as a beet\"** ‚Üí **Flushed skin**\n\n**\"Blind as a bat\"** ‚Üí **Mydriasis** ‚≠ê‚≠ê‚≠ê **(Dilated pupils - THIS CASE)**\n\n**\"Mad as a hatter\"** ‚Üí **Delirium, hallucinations**\n\n**\"Hot as a hare\"** ‚Üí **Hyperthermia** (no sweating) ‚≠ê **(THIS CASE)**\n\n**OTHER SYMPTOMS:**\n‚Ä¢ **Tachycardia**\n‚Ä¢ **Urinary retention**\n‚Ä¢ **Decreased bowel sounds**\n‚Ä¢ **Ataxia** (staggering gait) ‚≠ê **(THIS CASE)**\n\n**VS COCAINE:**\n‚Ä¢ Cocaine: **WET** (sweating) ‚ö†Ô∏è\n‚Ä¢ Dhatura: **DRY** ‚≠ê‚≠ê‚≠ê\n\n**VS OPIOIDS:**\n‚Ä¢ Opioids: **MIOSIS** (pinpoint pupils) ‚ö†Ô∏è\n‚Ä¢ Dhatura: **MYDRIASIS** ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **Physostigmine** (cholinesterase inhibitor) - reverses anticholinergic effects\n‚Ä¢ **Supportive** (cooling, benzodiazepines for agitation)\n\nüí° **KEY:** **Mydriasis + HOT DRY skin + Delirium = Dhatura (anticholinergic)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/page35_img78.jpg",
    year: 2024
  },{
    id: "neet-pg-2024-86",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In MTP at 28 weeks for congenital anomalies, whose presence is not required?",
    options: [
      "Obstetrician",
      "Lawyer",
      "Pediatrician",
      "Sonologist"
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Lawyer (Option B)**\n\nüî¨ **MTP >24 WEEKS (Substantial fetal anomaly):**\n\n**MEDICAL BOARD REQUIRED** ‚≠ê‚≠ê‚≠ê:\n\n**MUST INCLUDE:**\n‚Ä¢ **Obstetrician** ‚≠ê (assess pregnancy)\n‚Ä¢ **Pediatrician** ‚≠ê (assess fetal viability/anomaly)\n‚Ä¢ **Radiologist/Sonologist** ‚≠ê (confirm anomaly on imaging)\n‚Ä¢ May include geneticist, fetal medicine specialist\n\n**NOT REQUIRED:**\n‚Ä¢ **Lawyer** ‚≠ê‚≠ê‚≠ê **(ANSWER)** - Legal formalities separate, NOT part of medical board\n\n**PROCESS:**\n1. **Detection** of substantial fetal anomaly\n2. **Medical Board** evaluates\n3. If **lethal/serious anomaly** confirmed ‚Üí MTP allowed\n4. **No upper gestational limit** for substantial anomalies (MTP Act 2021)\n\n**SUBSTANTIAL FETAL ANOMALY:**\n‚Ä¢ **Lethal** or **incompatible with life**\n‚Ä¢ Would cause **serious handicap**\n‚Ä¢ Diagnosed by **Medical Board** only\n\nüí° **KEY:** **MTP >24 weeks = Medical Board (NOT lawyer)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-87",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A G5P4 woman comes for routine sonography for the first time. She has had four\ndaughters and wants a boy this time. She asks for sex determination. To be in line with\nthe above-depicted guidelines, what will you choose?",
    options: [
      "Will check routine ANC and sex for developmental abnormalities and do not reveal\ngender to the patient",
      "Will check routine ANC and sex for developmental abnormalities and reveal gender to\nthe patient",
      "Reveal gender if a girl",
      "Check only routine ANC, do not check sex"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Check routine ANC + sex for abnormalities, DO NOT reveal gender (Option A)**\n\nüî¨ **PC-PNDT ACT (Pre-Conception and Pre-Natal Diagnostic Techniques Act):**\n\n**PROHIBITS:**\n‚Ä¢ **Sex determination** for **sex selection** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Revealing fetal sex** to parents/family ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Advertisement** of sex determination services\n\n**ALLOWED:**\n‚Ä¢ **Sex determination** for **medical reasons** ONLY ‚≠ê:\n  ‚Üí **Sex-linked disorders** (hemophilia, Duchenne MD, etc.)\n  ‚Üí **Chromosomal abnormalities**\n  ‚Üí **Congenital adrenal hyperplasia**\n\n**THIS CASE:**\n‚Ä¢ **No medical indication** (wants boy for social reasons) ‚ö†Ô∏è\n‚Ä¢ **Can check** sex for developmental abnormalities ‚úì\n‚Ä¢ **CANNOT reveal** gender to patient ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**PENALTIES:**\n‚Ä¢ **Doctor:** Imprisonment (3-5 years) + fine (‚Çπ50,000-1 lakh)\n‚Ä¢ **License suspension/cancellation**\n‚Ä¢ **Patient:** Fine (‚Çπ50,000-1 lakh)\n\nüí° **KEY:** **Can check, CANNOT reveal (unless medical indication)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-89",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "A child was a victim of sexual assault, and a test was done using a perianal swab.\nWhat‚Äôs the name of this test? The test showed yellow needle-shaped crystals.",
    options: [
      "Barberio test",
      "Teichman test",
      "Takayama test",
      "Florence test"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Barberio test (Option A)**\n\nüî¨ **FORENSIC TESTS FOR SEMEN:**\n\n**BARBERIO TEST** ‚≠ê‚≠ê‚≠ê **(ANSWER)**:\n‚Ä¢ **Detects:** **Semen** (spermine/choline)\n‚Ä¢ **Reagent:** **Picric acid + sulphuric acid**\n‚Ä¢ **Result:** **Yellow needle-shaped crystals** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **Confirmatory** for semen\n‚Ä¢ Used in **sexual assault** cases\n\n**FLORENCE TEST:**\n‚Ä¢ **Detects:** Semen (choline)\n‚Ä¢ **Reagent:** Iodine + Iodide\n‚Ä¢ **Result:** **Brown rhomboid/needle crystals**\n‚Ä¢ **Presumptive** test\n\n**OTHER TESTS:**\n\n**TEICHMANN TEST:**\n‚Ä¢ **Detects:** **Blood** (hemoglobin) ‚ö†Ô∏è\n‚Ä¢ Brown rhomboid **hemin crystals**\n\n**TAKAYAMA TEST:**\n‚Ä¢ **Detects:** **Blood** (hemoglobin) ‚ö†Ô∏è\n‚Ä¢ Pink feathery **hemochromogen crystals**\n\n**ACID PHOSPHATASE TEST:**\n‚Ä¢ **Screening** test for semen (high in prostate)\n‚Ä¢ Quick, presumptive\n\nüí° **KEY:** **Yellow needle crystals = Barberio (semen)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2024-91",
    subjectId: "medicine",
    chapterId: "neet-pg-2024",
    question: "In a sexual assault case in court, ‚Äùin camera‚Äù trial refers to:",
    options: [
      "Closed court proceedings",
      "Recording of proceedings",
      "Open court proceedings",
      "Proceedings occurring in a different place"
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Closed court proceedings (Option A)**\n\nüî¨ **'IN CAMERA' TRIAL:**\n\n**DEFINITION:** **Private/Closed court proceedings** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n\n**CHARACTERISTICS:**\n‚Ä¢ **NOT open** to public ‚≠ê\n‚Ä¢ **NO media** allowed\n‚Ä¢ **Only essential persons** present:\n  ‚Üí Judge, lawyers, parties, witnesses\n‚Ä¢ **Protects privacy** of victim/accused\n‚Ä¢ **Latin:** \"In chamber\" (in private room)\n\n**USED IN:**\n‚Ä¢ **Sexual assault cases** ‚≠ê‚≠ê‚≠ê **(THIS CASE)**\n‚Ä¢ **Rape trials**\n‚Ä¢ **Child abuse cases**\n‚Ä¢ **National security matters**\n‚Ä¢ **Trade secrets**\n\n**PURPOSE:**\n‚Ä¢ **Protect victim** from public scrutiny ‚≠ê\n‚Ä¢ **Prevent secondary victimization**\n‚Ä¢ **Encourage testimony** (less intimidating)\n‚Ä¢ **Maintain dignity**\n\n**VS OPEN COURT:**\n‚Ä¢ Open court: **Public** can attend\n‚Ä¢ In camera: **Closed** to public ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **In camera = Closed/Private court (sexual assault)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2024
  },{
    id: "neet-pg-2023-93",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "Identify the condition associated with the murmur in the image below.",
    options: [
      "Mitral regurgitation",
      "Aortic regurgitation",
      "Aortic stenosis L",
      "Mitral stenosis",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Mitral regurgitation (Option A)**\n\nüî¨ **MITRAL REGURGITATION (MR):**\n\n**AUSCULTATION:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Holosystolic (pansystolic) murmur** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Blowing** quality\n‚Ä¢ **Best heard:** **Apex** (5th ICS, MCL)\n‚Ä¢ **Radiates:** **Axilla** ‚≠ê\n\n**CAUSES:**\n‚Ä¢ **Mitral valve prolapse** (most common)\n‚Ä¢ **Rheumatic heart disease**\n‚Ä¢ **Ischemic** (papillary muscle dysfunction)\n‚Ä¢ **Infective endocarditis**\n\n**FINDINGS:**\n‚Ä¢ **Displaced apex** (LV dilatation)\n‚Ä¢ **S3 gallop**\n‚Ä¢ **Soft S1**\n\n**ECHO:** **Regurgitant jet** from LV ‚Üí LA\n\n**TREATMENT:**\n‚Ä¢ **Medical:** Afterload reduction (ACE-I, ARBs)\n‚Ä¢ **Surgical:** Valve repair/replacement (if severe)\n\nüí° **KEY:** **Holosystolic murmur at apex ‚Üí axilla = MR** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-96",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A young man came to thpe medical OPD with complaints of early morning backache and stiffness, which improves on exercise, and persistent red eyes. On examination, lung expansion was less than 3 cm. X-ray is shown in the image given below. e r P r e d d a L p What is the most probable diagnosis?",
    options: [
      "Ankylosing spondylitis",
      "Paget's diseas r",
      "HPealed tuberculosis",
      "O steopetrosis",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Ankylosing spondylitis (Option A)**\n\nüî¨ **ANKYLOSING SPONDYLITIS (AS):**\n\n**CLASSIC TRIAD** ‚≠ê‚≠ê‚≠ê:\n1. **Morning stiffness** (>30 min) ‚≠ê‚≠ê‚≠ê\n2. **Improves with exercise** ‚≠ê‚≠ê‚≠ê\n3. **Young male** (20-30 years)\n\n**THIS CASE:**\n‚Ä¢ **Morning backache + stiffness** ‚≠ê\n‚Ä¢ **Improves on exercise** ‚≠ê\n‚Ä¢ **Red eyes** (uveitis) ‚≠ê\n‚Ä¢ **Reduced chest expansion** (<2.5 cm) ‚≠ê‚≠ê‚≠ê\n\n**X-RAY:**\n‚Ä¢ **\"Bamboo spine\"** ‚≠ê‚≠ê‚≠ê (syndesmophytes)\n‚Ä¢ **Sacroiliitis** (bilateral)\n‚Ä¢ **Squaring of vertebrae**\n\n**EXTRAARTICULAR:**\n‚Ä¢ **Anterior uveitis** (25%) ‚≠ê\n‚Ä¢ **Aortic regurgitation**\n‚Ä¢ **Apical lung fibrosis**\n\n**GENETICS:** **HLA-B27 positive** (90%) ‚≠ê\n\n**TREATMENT:**\n‚Ä¢ **NSAIDs** (first-line)\n‚Ä¢ **TNF inhibitors** (if refractory)\n\nüí° **KEY:** **Morning stiffness + Improves with exercise + Reduced chest expansion = AS** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-97",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A patient with hyperkalemia and elevated urea levels underwent dialysis. Towards the end of the session, she became drowsy and had a sudden seizure episode. On examination, the patient was hypotensive. What is the treatment for this condition?",
    options: [
      "Bumetanide",
      "Ethacrynic acid",
      "Nesiritide",
      "IV Mannitol r",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **IV Mannitol (Option D)**\n\nüî¨ **DIALYSIS DISEQUILIBRIUM SYNDROME:**\n\n**CAUSE:** **Rapid dialysis** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Rapid urea clearance** from blood ‚Üí brain lags behind\n‚Ä¢ **Osmotic gradient** ‚Üí **Water shifts into brain**\n‚Ä¢ **Cerebral edema** ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Towards end of dialysis** ‚≠ê\n‚Ä¢ **Drowsiness** ‚≠ê\n‚Ä¢ **Seizures** ‚≠ê\n‚Ä¢ **Hypotension**\n‚Ä¢ **Nausea**, **headache**\n\n**TREATMENT:**\n‚Ä¢ **IV Mannitol** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n  - **Osmotic diuretic**\n  - **Reduces cerebral edema**\n‚Ä¢ **Hypertonic saline** (alternative)\n\n**PREVENTION:**\n‚Ä¢ **Slow dialysis** (first session)\n‚Ä¢ **Short sessions initially**\n‚Ä¢ **Mannitol prophylaxis**\n\nüí° **KEY:** **Seizure during/after dialysis = Disequilibrium syndrome ‚Üí Mannitol** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-98",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A female patient presents to the emergency depadrtment with severe restlessness, palpitations, and tremors. She is a known case of bronchial asthma. On examination, the neck looks swollen. Blood pressure is elevated, and tachycardia is noted. ECG shows atrial fibrillation. Which of the following drugs is used for imamediate management in this patient?",
    options: [
      "Diltiazem L",
      "Propranolol p",
      "Esmolol",
      "Propylthiouracil",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Diltiazem (Option A)**\n\nüî¨ **THYROID STORM + ATRIAL FIBRILLATION:**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Thyrotoxicosis** (restlessness, tremors, tachycardia) ‚≠ê\n‚Ä¢ **Atrial fibrillation** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Known asthma** ‚≠ê‚≠ê‚≠ê **(KEY)**\n\n**IMMEDIATE RATE CONTROL:**\n\n**DILTIAZEM** ‚≠ê‚≠ê‚≠ê **(ANSWER - Calcium channel blocker)**\n‚Ä¢ **Safe in asthma** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Controls ventricular rate**\n‚Ä¢ **IV loading:** 0.25 mg/kg\n\n**WHY NOT Œ≤-BLOCKERS:**\n‚Ä¢ **Propranolol/Esmolol:** CONTRAINDICATED in asthma ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Bronchospasm risk**\n\n**ALSO GIVE:**\n‚Ä¢ **PTU/Methimazole** (block synthesis)\n‚Ä¢ **Lugol's iodine** (after 1 hour)\n‚Ä¢ **Hydrocortisone**\n‚Ä¢ **Cooling**, **fluids**\n\nüí° **KEY:** **Thyroid storm + AF + Asthma = Diltiazem (NOT Œ≤-blocker)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page48_img29.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-101",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "p A 30-year-old male is found to be positive for HBsAg and HBeAg and is diagnosed with chronic hepatitis B. The patient's viral load was 2x 100000 and SGPT is found to be doubled. e What is the appropriate management in this patient? SGPT-Serum glutamate pyruvate transaminase",
    options: [
      "Lamivudine for 30+ weeks OP2: Tenofovir for> 40 weeks O 3: Pegylated interferon for 52 weeks O4: Combined pegylated interferon with lamivudine",
      "Option 2",
      "Option 3",
      "Combined pegylated interferon with lamivudine",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Tenofovir for >40 weeks (Option B)**\n\nüî¨ **CHRONIC HEPATITIS B MANAGEMENT:**\n\n**THIS CASE - ACTIVE DISEASE:**\n‚Ä¢ **HBsAg + HBeAg positive** ‚≠ê\n‚Ä¢ **High viral load** (2√ó10‚Åµ) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Elevated ALT** (doubled) ‚≠ê\n\n**INDICATIONS FOR TREATMENT:**\n‚Ä¢ **HBeAg positive** + **HBV DNA >20,000 IU/mL** + **ALT >2√ó ULN** ‚≠ê‚≠ê‚≠ê\n\n**FIRST-LINE TREATMENT:**\n\n**1. Tenofovir** ‚≠ê‚≠ê‚≠ê **(PREFERRED)**\n‚Ä¢ **Nucleotide analog**\n‚Ä¢ **High genetic barrier** (low resistance)\n‚Ä¢ **Duration:** Indefinite (until HBeAg seroconversion + 12 months) ‚≠ê\n‚Ä¢ **Minimum:** 48 weeks\n\n**2. Entecavir** (alternative)\n\n**PEGYLATED INTERFERON:**\n‚Ä¢ **48 weeks** (finite duration)\n‚Ä¢ **Side effects** (flu-like, depression)\n‚Ä¢ Second-line\n\nüí° **KEY:** **Active CHB (HBeAg+, high VL, ‚ÜëALT) ‚Üí Tenofovir (>48 weeks)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-102",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 25-year-old male patient complained of palpitations, sweating, and restlessness. He has a complaint of sweaty palms. Clinical findings are depicted in the image given below. r What is the diagnostic test done on this patient? e",
    options: [
      "Anti-thyroglobulin antibody d",
      "Anti-thyroid peroxidase antibody",
      "Thyroid receptor antibody",
      "Elevated ultrasensitive thyrotropin levels a",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Thyroid receptor antibody (TSH receptor antibody) (Option C)**\n\nüî¨ **GRAVES' DISEASE:**\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Palpitations**, **sweating**, **restlessness** ‚≠ê\n‚Ä¢ **Sweaty palms** ‚≠ê\n‚Ä¢ **Thyrotoxicosis symptoms**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **Autoantibodies** against **TSH receptor** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Stimulate** thyroid ‚Üí **Hyperthyroidism**\n\n**DIAGNOSTIC TEST:**\n‚Ä¢ **TSH receptor antibody (TRAb)** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Positive in 90%** of Graves' disease\n‚Ä¢ **Stimulating antibodies**\n\n**OTHER FINDINGS:**\n‚Ä¢ **Low TSH**, **High T4/T3**\n‚Ä¢ **Diffuse goiter**\n‚Ä¢ **Exophthalmos** (if present)\n‚Ä¢ **Pretibial myxedema**\n\n**WHY NOT OTHERS:**\n‚Ä¢ **Anti-TPO/Anti-Tg:** Hashimoto's thyroiditis\n‚Ä¢ **High TSH:** Hypothyroidism\n\nüí° **KEY:** **Graves' disease ‚Üí TSH receptor antibody (TRAb)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page50_img30.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-103",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 50-year-old HIV patient presented with a painless lesion, as shown in the image. e r P r e d d a L What is the most likely diagnosis? p",
    options: [
      "Basal cell carcinoma",
      "Kaposi sarcoma",
      "Malignant mrelanoma",
      "P Squamous cell carcinoma",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Kaposi sarcoma (Option B)**\n\nüî¨ **KAPOSI SARCOMA (KS):**\n\n**AIDS-DEFINING ILLNESS** ‚≠ê‚≠ê‚≠ê\n\n**CAUSE:** **HHV-8** (Human herpesvirus 8) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **HIV-positive** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Painless lesions** ‚≠ê\n‚Ä¢ **Purple/violaceous plaques/nodules** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Multiple sites** (skin, oral, GI, lung)\n\n**APPEARANCE:**\n‚Ä¢ **Purple-red-brown** patches/plaques\n‚Ä¢ **Non-blanching**\n‚Ä¢ **Raised**, **vascular**\n\n**DIAGNOSIS:** **Biopsy** (spindle cells)\n\n**TREATMENT:**\n‚Ä¢ **HAART** (first-line) ‚≠ê‚≠ê‚≠ê (improves CD4, controls KS)\n‚Ä¢ **Local:** Radiation, intralesional chemo\n‚Ä¢ **Systemic:** Liposomal doxorubicin (if extensive)\n\n**TYPES:**\n‚Ä¢ **Epidemic** (AIDS-related) - most aggressive\n‚Ä¢ Classic, Endemic, Iatrogenic\n\nüí° **KEY:** **HIV + Purple painless lesions = Kaposi sarcoma (HHV-8)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-106",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "Question 106 - [Content needs manual review]",
    options: [
      "Option 1",
      "Hippocampus",
      "Cerebellum",
      "Premotor cortex",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Option 1**\n\nüî¨ Detailed explanation to be added.",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page52_img31.jpeg",
    year: 2023
  },{
    id: "neet-pg-2023-107",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 45-year-old HIV-positive male complained of persistent cough and weight loss. He has skin lesions that appear as umbilicated papules and nodules predominantly on the face, trunk, and upper extremities. Chest x-ray showed multiple bilateral nodular infiltrates. His sputum CBNAAT for tuberculosis was negative, and he has a low CD4 count. What is th e probable diagnosis? r",
    options: [
      "HIV with disseminated histoplasmosis",
      "HIV with disseminated cryptococcosis d",
      "HIV with molluscum contagiosum d",
      "HIV with tuberculosis",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **HIV with disseminated histoplasmosis (Option A)**\n\nüî¨ **DISSEMINATED HISTOPLASMOSIS IN AIDS:**\n\n**ORGANISM:** **Histoplasma capsulatum** ‚≠ê‚≠ê‚≠ê (fungus)\n\n**THIS CASE - KEY FEATURES:**\n‚Ä¢ **HIV + Low CD4** (<100) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Umbilicated papules/nodules** ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n‚Ä¢ **Face, trunk, extremities**\n‚Ä¢ **Bilateral lung nodules** ‚≠ê\n‚Ä¢ **Negative TB test**\n\n**SKIN LESIONS:**\n‚Ä¢ **Molluscum-like** (umbilicated) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **BUT:** Disseminated disease (lungs + skin)\n\n**DIAGNOSIS:**\n‚Ä¢ **Histoplasma antigen** (urine/serum) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Culture** (blood, bone marrow)\n‚Ä¢ **Biopsy:** Intracellular yeast\n\n**TREATMENT:**\n‚Ä¢ **Amphotericin B** (induction) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Itraconazole** (maintenance)\n\n**VS MOLLUSCUM:**\n‚Ä¢ **Pure molluscum:** Skin only, NO systemic disease\n\nüí° **KEY:** **AIDS + Umbilicated lesions + Lung nodules = Disseminated histoplasmosis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-109",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A male patient presented to the emergency room with seizures. He has a history of fever, headache, and confusion. An MRI brain was done, and it showed inflammation involving the bitemporal lobe. What is the most likely aetiology for this presentation?",
    options: [
      "Cytomegalovirus",
      "Toxoplasma gondii",
      "Herpes simplex virus r",
      "Mycobacterium tuberculosis e",
    ],
    correctAnswer: 2,
    explanation: "‚úÖ ANSWER: **Herpes simplex virus (HSV) (Option C)**\n\nüî¨ **HERPES SIMPLEX ENCEPHALITIS (HSE):**\n\n**MOST COMMON** sporadic viral encephalitis ‚≠ê‚≠ê‚≠ê\n\n**ORGANISM:** **HSV-1** (>95%) ‚≠ê‚≠ê‚≠ê\n\n**CLINICAL (THIS CASE):**\n‚Ä¢ **Fever**, **headache**, **confusion** ‚≠ê\n‚Ä¢ **Seizures** ‚≠ê‚≠ê‚≠ê (focal)\n‚Ä¢ **Behavioral changes**\n‚Ä¢ **Olfactory/gustatory hallucinations**\n\n**KEY IMAGING:** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **MRI:** **Bitemporal lobe** involvement ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n‚Ä¢ **Hemorrhagic necrosis**\n‚Ä¢ **Medial temporal**, **inferior frontal** lobes\n\n**DIAGNOSIS:**\n‚Ä¢ **CSF PCR for HSV** ‚≠ê‚≠ê‚≠ê (gold standard)\n‚Ä¢ **CSF:** Lymphocytic pleocytosis, RBCs\n\n**TREATMENT:**\n‚Ä¢ **IV Acyclovir** ‚≠ê‚≠ê‚≠ê (10 mg/kg q8h √ó 14-21 days)\n‚Ä¢ **Start empirically** (don't wait for confirmation)\n\nüí° **KEY:** **Seizures + Confusion + Bitemporal involvement = HSV encephalitis** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-111",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A male patient presents with senLsory loss and weakness of limbs for 3 months. He also has angular stomatitis. On examination, there is loss of proprioception, vibration sensations, UMN type of lower limb weakness, and absent ankle reflex. What is the most probable diagnosis? p",
    options: [
      "Extradural cord compression e",
      "Amyotrophic lateral sclerosis",
      "Multiple sclerosis OP4: Subacute combined degeneration of cor A ns: 4",
      "Option 4",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Subacute combined degeneration of cord (Option D)**\n\nüî¨ **SUBACUTE COMBINED DEGENERATION (SCD):**\n\n**CAUSE:** **Vitamin B12 deficiency** ‚≠ê‚≠ê‚≠ê\n\n**KEY FEATURES (THIS CASE):**\n\n**1. Angular stomatitis** ‚≠ê‚≠ê‚≠ê (B12 deficiency sign)\n\n**2. COMBINED findings** ‚≠ê‚≠ê‚≠ê:\n‚Ä¢ **Dorsal columns:** Loss of proprioception, vibration ‚≠ê\n‚Ä¢ **Lateral corticospinal:** UMN signs (weakness, spasticity) ‚≠ê\n‚Ä¢ **Peripheral neuropathy:** Absent ankle reflex ‚≠ê\n\n**3. Subacute onset** (weeks-months)\n\n**TRIAD:**\n‚Ä¢ **Myelopathy** (UMN + dorsal column)\n‚Ä¢ **Peripheral neuropathy** (LMN)\n‚Ä¢ **Dementia** (if severe)\n\n**DIAGNOSIS:**\n‚Ä¢ **Low serum B12** (<200 pg/mL)\n‚Ä¢ **Elevated homocysteine, methylmalonic acid**\n‚Ä¢ **MRI:** T2 hyperintensity (posterior columns)\n\n**TREATMENT:** **IM Vitamin B12** ‚≠ê‚≠ê‚≠ê\n\nüí° **KEY:** **B12 deficiency + UMN + Dorsal column + LMN = SCD** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-134",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A patient who is a known case of hyperteansion on multiple anti-hypertensive medications came to OPD. His ECG finding is given below. Which of the following drugs is responsible for the ECG finding? L p e r P",
    options: [
      "Prazosin",
      "Metoprolol",
      "Hydrochlorothiazide",
      "Spironolactone",
    ],
    correctAnswer: 3,
    explanation: "‚úÖ ANSWER: **Spironolactone (Option D)**\n\nüî¨ **SPIRONOLACTONE & ECG CHANGES:**\n\n**ECG FINDING:** Likely **HYPERKALEMIA** ‚≠ê‚≠ê‚≠ê\n\n**SPIRONOLACTONE:**\n‚Ä¢ **Potassium-sparing diuretic** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Aldosterone antagonist**\n‚Ä¢ **Causes HYPERKALEMIA** ‚≠ê‚≠ê‚≠ê\n\n**HYPERKALEMIA ECG CHANGES:** (Progressive)\n1. **Peaked T waves** ‚≠ê‚≠ê‚≠ê (earliest)\n2. **Prolonged PR**\n3. **Wide QRS**\n4. **Loss of P wave**\n5. **Sine wave** (pre-arrest)\n\n**OTHER DRUGS:**\n‚Ä¢ **Prazosin:** Alpha blocker (no K+ effect)\n‚Ä¢ **Metoprolol:** Beta blocker (no K+ effect)\n‚Ä¢ **HCTZ:** Thiazide ‚Üí **HYPOKALEMIA** (opposite)\n\n**TREATMENT:**\n‚Ä¢ **Stop spironolactone** ‚≠ê\n‚Ä¢ **Calcium gluconate** (cardiac protection)\n‚Ä¢ **Insulin + glucose** (shift K+ intracellularly)\n\nüí° **KEY:** **Spironolactone ‚Üí Hyperkalemia ‚Üí Peaked T waves on ECG** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-135",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 78-year-old woman presents with a progressive decline in daily activity. She gives a history of convulsions and visual hallucinations. She does not talk to anyone and keeps looking at the sky. Pathological examination shows the presence of Lewy bodies within the neurons. What is r the most probable diagnosis? e",
    options: [
      "Parkinson's disease",
      "Prion disease",
      "Huntington's chorea",
      "Alzheimer's diseas a",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Dementia with Lewy Bodies (DLB) - but answer is Parkinson's disease (Option A)**\n\nüî¨ **LEWY BODY DEMENTIA (DLB):**\n\n**THIS CASE - CLASSIC FEATURES:**\n‚Ä¢ **Progressive cognitive decline** ‚≠ê\n‚Ä¢ **Visual hallucinations** ‚≠ê‚≠ê‚≠ê **(CHARACTERISTIC)**\n‚Ä¢ **Fluctuating cognition** (staring at sky)\n‚Ä¢ **Lewy bodies** in neurons ‚≠ê‚≠ê‚≠ê\n\n**CORE FEATURES (2+ for diagnosis):**\n1. **Fluctuating cognition** ‚≠ê\n2. **Visual hallucinations** ‚≠ê‚≠ê‚≠ê\n3. **REM sleep behavior disorder**\n4. **Parkinsonism** (rigidity, tremor)\n\n**PATHOLOGY:**\n‚Ä¢ **Lewy bodies** (Œ±-synuclein aggregates) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Cortical distribution** (vs PD: substantia nigra)\n\n**VS PARKINSON'S:**\n‚Ä¢ **PD:** Motor >> Cognitive (dementia late)\n‚Ä¢ **DLB:** Cognitive + Motor together\n\n**VS ALZHEIMER'S:**\n‚Ä¢ **AD:** Memory loss, no hallucinations early\n‚Ä¢ **Neurofibrillary tangles** (not Lewy bodies)\n\nüí° **KEY:** **Visual hallucinations + Lewy bodies = DLB (spectrum with PD)** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-136",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A patient came to the medical OPD with complaints of polyuria. He has a history of undergoing total hypophyseectomy. His Na+ levels are found to be 155 mEq/ L, urine osmolarity was 200 mOsm/L. What is the definitive management in this patient?",
    options: [
      "DDAVP for 2 weeks and then discontinu P",
      "DDAVP supplementation for lifelong",
      "Upsetting of receptors so no treatment is required",
      "Thiazides for 2 weeks",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **DDAVP supplementation for lifelong (Option B)**\n\nüî¨ **CENTRAL DIABETES INSIPIDUS (Post-hypophysectomy):**\n\n**THIS CASE:**\n‚Ä¢ **Total hypophysectomy** ‚≠ê‚≠ê‚≠ê (pituitary removed)\n‚Ä¢ **Polyuria** ‚≠ê\n‚Ä¢ **Hypernatremia** (Na+ 155 mEq/L) ‚≠ê\n‚Ä¢ **Low urine osmolality** (200 mOsm/L) ‚≠ê\n‚Ä¢ = **CENTRAL DI**\n\n**PATHOPHYSIOLOGY:**\n‚Ä¢ **No ADH production** ‚≠ê‚≠ê‚≠ê (pituitary removed)\n‚Ä¢ **Cannot concentrate urine**\n‚Ä¢ **Water loss** ‚Üí Hypernatremia\n\n**TREATMENT:**\n‚Ä¢ **DDAVP (Desmopressin) LIFELONG** ‚≠ê‚≠ê‚≠ê **(ANSWER)**\n‚Ä¢ **Synthetic ADH analog**\n‚Ä¢ **Cannot recover** (no pituitary)\n‚Ä¢ **Intranasal or oral**\n\n**MONITORING:**\n‚Ä¢ **Serum sodium**\n‚Ä¢ **Urine output**\n‚Ä¢ **Avoid overtreatment** (hyponatremia)\n\n**WHY NOT OTHERS:**\n‚Ä¢ **2 weeks only:** Inadequate (permanent DI)\n‚Ä¢ **Thiazides:** For nephrogenic DI (not central)\n\nüí° **KEY:** **Post-hypophysectomy DI = Lifelong DDAVP** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-137",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A 65-year-old chronic smoker came to the medicine outpatient department with complaints of upper chest discomfort and drooping of an eyelid. He also complained of pain radiating to the upper arm and a tingling sensation in the 4th and 5th digits of his left hand. The chest X-ray is given below. r e d d a L p Which of the folleowing is the most likely diagnosis?",
    options: [
      "Pancoast tumou r",
      "Upper lobe pneumoni P",
      "Superior vena cava obstruction",
      "Aspergilloma",
    ],
    correctAnswer: 0,
    explanation: "‚úÖ ANSWER: **Pancoast tumor (Superior sulcus tumor) (Option A)**\n\nüî¨ **PANCOAST TUMOR (SYNDROME):**\n\n**LOCATION:** **Lung apex** (superior sulcus) ‚≠ê‚≠ê‚≠ê\n\n**THIS CASE - CLASSIC FEATURES:**\n‚Ä¢ **Chronic smoker** ‚≠ê\n‚Ä¢ **Horner's syndrome** (drooping eyelid) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Shoulder/chest pain** (T1 involvement) ‚≠ê\n‚Ä¢ **C8-T1 symptoms** (4th & 5th digit tingling) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **Upper lobe mass** on CXR\n\n**PANCOAST SYNDROME (Triad):**\n1. **Horner's syndrome** ‚≠ê‚≠ê‚≠ê (ptosis, miosis, anhidrosis)\n   - **Sympathetic chain** invasion\n2. **Shoulder/arm pain** ‚≠ê\n   - **Brachial plexus** (C8-T1) invasion\n3. **Upper lobe mass**\n\n**DIAGNOSIS:**\n‚Ä¢ **CT/MRI** chest\n‚Ä¢ **Biopsy** (usually NSCLC - squamous/adenocarcinoma)\n\n**TREATMENT:**\n‚Ä¢ **Neoadjuvant chemoradiation** ‚≠ê\n‚Ä¢ **Surgical resection** (if resectable)\n\nüí° **KEY:** **Lung apex mass + Horner's + C8-T1 involvement = Pancoast tumor** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    year: 2023
  },{
    id: "neet-pg-2023-138",
    subjectId: "medicine",
    chapterId: "neet-pg-2023",
    question: "A chronic alcoholic patient presents with acute pain and swelling of the left great toe. There is no history of trauma. Synovial fluid analysis shows raised leukocytes. Lab investigations show normal serum uric acid levels. What is the most likely diagnosis?",
    options: [
      "Pseudogout",
      "Acute gout",
      "Reactive arthritis",
      "Septic arthritis r",
    ],
    correctAnswer: 1,
    explanation: "‚úÖ ANSWER: **Acute gout (Option B)**\n\nüî¨ **ACUTE GOUT:**\n\n**THIS CASE:**\n‚Ä¢ **Chronic alcoholic** ‚≠ê\n‚Ä¢ **Acute pain/swelling** of **1st MTP** (great toe) ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **No trauma**\n‚Ä¢ **NORMAL serum uric acid** ‚≠ê‚≠ê‚≠ê **(KEY POINT)**\n\n**IMPORTANT:** **Serum uric acid CAN BE NORMAL during acute attack** ‚≠ê‚≠ê‚≠ê\n‚Ä¢ **~30% of acute gout** has normal uric acid\n‚Ä¢ **During attack:** Uric acid precipitates in joint\n‚Ä¢ **Serum level drops** temporarily\n\n**DIAGNOSIS:**\n‚Ä¢ **Synovial fluid analysis** ‚≠ê‚≠ê‚≠ê (GOLD STANDARD)\n‚Ä¢ **Needle-shaped negatively birefringent crystals** (under polarized light)\n‚Ä¢ **Monosodium urate crystals**\n\n**RISK FACTORS:**\n‚Ä¢ **Alcohol** ‚≠ê (especially beer)\n‚Ä¢ **High purine diet**\n‚Ä¢ **Diuretics**\n\n**TREATMENT:**\n‚Ä¢ **NSAIDs** (indomethacin) ‚≠ê\n‚Ä¢ **Colchicine**\n‚Ä¢ **Corticosteroids**\n\nüí° **KEY:** **Normal uric acid does NOT exclude acute gout** ‚≠ê‚≠ê‚≠ê",
    difficulty: "medium",
    imageUrl: "/images/questions/2023/page68_img37.jpeg",
    year: 2023
  }
];

export default questions;

// Helper function to get questions by chapter
export function getQuestionsByChapter(chapterId: string): Question[] {
  return questions.filter(q => q.chapterId === chapterId);
}

// Export question count
export const questionCount = questions.length;
